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Abstract 
 
High blood pressure (hypertension; HTN) is the leading risk factor for death, yet the 
precise causes are unclear. The nervous system is known to play a role in some forms of 
HTN and research has pointed to the kidneys as a likely neural target in HTN.  This 
possibility has been strengthened by recent clinical trials showing that ablation of the 
renal nerves (renal denervation; RDNX) has a significant antihypertensive effect in drug 
resistant patients. However, failure of the most recent sham-controlled trial has raised 
many questions regarding this treatment. Chief among them is whether the 
antihypertensive effect of RDNX is due to changes in kidney function secondary to 
ablation of sympathetic (efferent) renal nerves, or due to a reduction in non-renal 
sympathetic nerve activity secondary to ablation of sensory (afferent) renal nerves. In 
order to address this question, I first identified an animal model of HTN in which RDNX 
had an antihypertensive effect. Importantly, I showed that RDNX had roughly the same 
effect on blood pressure in hypertensive Dahl salt-sensitive (S) rats as has been reported 
in clinical trials. I then developed and validated a novel method for selective ablation of 
afferent renal nerves (renal-CAP treatment). Using this method, I showed that afferent 
renal nerves are not necessary to maintain cardiovascular or sodium/water homeostasis in 
normotensive rats subjected to dietary sodium loading. We also showed that renal-CAP 
treatment and complete RDNX caused the same attenuation of deoxycorticosterone-salt 
HTN, suggesting that the antihypertensive effect of RDNX in this model is due to 
ablation of afferent renal nerves. Lastly, we showed that RDNX has the same 
antihypertensive effect in Dahl S rats with mild HTN (after three weeks of high salt 
feeding) and in those with severe HTN (after nine weeks of high salt feeding). These 
results suggest that the antihypertensive effect of RDNX in the Dahl S rat is not 
dependent on duration of high salt feeding or pretreatment blood pressure and that the 
antihypertensive effect of RDNX in this model is not due to ablation of afferent renal 
nerves.  
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Chapter One 
 
Introduction 
 
 
 
 
 
 
1.1 Background 
 
High blood pressure (hypertension, HTN) is a major contributor to death and disability, 
worldwide. In fact, due to the causal links between HTN and many major health 
problems including heart failure and stroke, HTN is currently the number one risk factor 
for death and the number three risk factor for disease burden worldwide (108). Moreover, 
the prevalence of HTN is staggering. An estimated one billion people currently have 
HTN and this number is expected to rise to 1.5 billion by the year 2025 (90). Despite 
these worrying figures, the causes of HTN are still largely unknown and treatment 
remains poor with pharmacological therapy failing to reduce blood pressure to an 
acceptable range in an estimated 10-15% of hypertensive patients (1). 
 While it is difficult to pin down the precise etiology of HTN in most patients, 
decades of experiments performed in people as well as various animal models have 
revealed a number of possible contributors. Perhaps the most well studied contributor to 
HTN is the kidney. In fact, renal excretory function has been proposed to be the “rate 
limiting step” in HTN in that arterial pressure (AP) cannot increase chronically unless 
renal excretory function is impaired. The reasoning behind this hypothesis is that AP is 
correlated with urinary sodium excretion and urine flow rate (pressure-
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natriuresis/diuresis) such that increases in AP lead to excretion of salt and water, a 
decrease in blood volume and return of AP to normal levels. Therefore, it has been 
suggested that in order for AP to be increased chronically, pressure-natriuresis/diuresis 
must be impaired (58). While this obligatory impaired pressure-natriuresis/diuresis 
hypothesis is intriguing, mounting evidence suggest that other factors can and do 
contribute to HTN in the absence of changes in renal sodium and water handling.  
 The sympathetic nervous system (SNS) is one such factor that has been 
implicated in the pathogenesis of HTN. Global, renal, cardiac and skeletal muscle 
sympathetic activity have been shown to be elevated in human hypertensives (142) and 
pharmacological as well as surgical blockade of the SNS have been shown to reduce AP 
in various animal models of HTN as well as in hypertensive patients (38, 134). Poor 
tolerance to global sympathetic blockade and invasive surgical procedures led to the 
abandonment of these therapies for treatment of HTN for many years. Recently however, 
technological advances have reignited interest in targeting the SNS for treatment of HTN. 
 It has been known for over a century that the nervous system exhibits great 
influence over renal function. Some of the earliest experiments were performed by 
Claude Bernard in the 1850s in which he denervated the kidneys and noted ureteral 
distension. Later studies showed that stimulation of the renal nerves had an antidiuretic 
effect. Decades of research since then have elucidated a great deal more about the nature 
of neural influence on renal function. Additional research has revealed the kidney as a 
sensory organ that sends information back to the central nervous system (CNS) via 
afferent sensory nerves. 
 Sympathetic innervation of the kidneys is known to have pro-hypertensive effects 
such as enhancing sodium reabsorption, increasing renal vascular resistance and 
stimulating renin release. Because of these sympathetic actions, the role of the renal 
nerves in HTN has been investigated for decades. Specifically, ablation of the renal 
nerves (renal denervation, RDNX) has been performed in nearly every major 
hypertensive animal model with varying effects on AP. While it does not always produce 
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an antihypertensive effect, RDNX has been shown to lower AP both in normotensive rats 
and in many animal models of HTN (38, 76).  
 Numerous studies demonstrating the possible therapeutic effect of RDNX coupled 
with recent technological advances have led to the development of a catheter based 
RDNX for the treatment in humans. During this minimally invasive procedure, a device 
is introduced into the renal arteries through a catheter in the femoral artery and, using 
radiofrequency ablation, the device destroys the nerves running to and from the kidneys. 
Initial clinical data showed a significant and sustained antihypertensive effect of RDNX 
in severely hypertensive, drug resistant patients (42, 101).  Although these results were 
exciting, they sparked a number of important questions regarding the antihypertensive 
mechanisms underlying the therapeutic effect of this new treatment.  
 The mechanistic questions surrounding RDNX have become even more important 
in the past year wherein data from the first major multicenter sham-controlled double 
blinded clinical trial of RDNX were released (13). In this study, not only did RDNX have 
a much smaller antihypertensive effect than in previous clinical trials, but patients who 
underwent RDNX did not have a statistically significant decrease in AP when compared 
to sham operated individuals. While these results have sparked a great deal of debate over 
why this trial failed after the plethora of positive data previously reported, they also 
highlight two important points. First, these data suggest that RDNX may not be an 
effective treatment for HTN in all people. Second, these data highlight the importance of 
further basic science research, which must be done in order to better understand how 
RDNX lowers AP when it does in order to optimize treatment efficacy. 
 Perhaps the most discussed mechanistic question surrounding this treatment is 
whether the antihypertensive effect of RDNX is due to ablation of afferent or efferent 
renal nerves. When this treatment was initially developed, the rationale was that because 
the renal sympathetic nerves (efferent renal nerves) influence sodium reabsorption, renal 
vascular tone and plasma renin concentration, removal of the neural influence on these 
pro-hypertensive mechanisms would cause a reduction in AP. Indeed there is some 
evidence to suggest that this may explain the antihypertensive effect of RDNX. 
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Specifically, it has been shown that a decrease in renal resistive index accompanies a fall 
in AP in patients following RDNX (112). While this is compelling, the lack of 
additionally evidence makes it less than conclusive. Additionally, there is no evidence 
that the antihypertensive effect of RDNX is associated with a decrease in plasma renin 
concentration or an unloading of salt and water. 
 An alternate explanation for the antihypertensive effect of RDNX is that ablation 
of sympathoexcitatory renal sensory nerves (afferent renal nerves) causes a reduction in 
sympathetically mediated peripheral vasoconstriction. While this has not been shown 
directly, there are a number of observations that suggest sympathetic outflow is indeed 
reduced by RDNX. Specifically, RDNX has been associated with reductions in muscle 
sympathetic nerve activity, plasma glucose concentration, cardiac arrhythmias and 
episodes of sleep apnea (67, 149, 171). It should be noted that one study found no change 
in muscle sympathetic nerve activity following RDNX; however, there was also no 
change in AP leaving open the possibility that the blood pressure lowering effect of 
RDNX is due to reductions in sympathetic nerve activity (18). 
 To begin to address the differential role of afferent and efferent renal nerves in 
HTN, I will first review what is currently known about these nerves. I will discuss the 
anatomy, functions and mechanisms of acute and chronic activation of both efferent and 
afferent renal nerves and then review what is known about the differential role of afferent 
and efferent renal nerves in various forms of HTN before presenting my own work.  
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1.2 Efferent renal nerves 
 
Gross anatomy of the renal nerves 
 The gross anatomy of the renal nerves is depicted in Figure 1. The renal nerves 
course along the renal arteries and veins in a sort of meshwork that penetrates the walls of 
the vessels into the tunica media (8). While the majority of the renal nerve fibers run 
from the aorta to the hilum of the kidney, there are some renal nerve bundles that course 
toward and join the renal nerve plexus at various points between the aorta and kidney. As 
is true with many nerves throughout the body, the renal nerves contain multiple different 
fiber types. Specifically, the renal nerves contain both sympathetic (efferent) fibers which 
course from sympathetic ganglia to the kidneys, and sensory (afferent) fibers which 
course from the kidneys to the spinal cord. The specific anatomy and mechanisms of 
neurotransmission of both afferent and efferent renal nerves are discussed below. 
 
Anatomy of efferent renal nerves 
 As with many sympathetic nerves, the cell bodies of the renal sympathetic 
preganglionic neurons reside in the intermediolateral (IML) cell column of the spinal 
cord. These neurons then send axons out of the spinal cord via the ventral horns which 
synapse onto sympathetic postganglionic fibers in the sympathetic ganglia. The IML, in 
turn receives input from various brain regions. With regard to the renal sympathetic 
nerves specifically, the primary neural input into the IML arises from the rostral 
ventrolateral medulla (RVLM). This important cardiovascular regulatory region of the 
medulla receives input from a number of other brain nuclei. By in large, the RVLM 
receives excitatory input from the paraventricular nucleus of the hypothalamus (PVN) 
and inhibitory input from the nucleus of the solitary tract (NTS) and the caudal 
ventrolateral medulla (CVLM). It should be noted that the PVN also has direct input into 
the IML bypassing the RVLM. The PVN in turn receives excitatory input from three 
important regions of the forebrain, the median preoptic nucleus (MnPO) and two of the 
circumventricular organs (CVOs), the subfornical organ (SFO) and the organum 
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vasculosum of the lamina terminalis (OVLT). This network of brain regions is illustrated 
in Figure 2. The importance of these nuclei in the regulation of efferent renal sympathetic 
nerve activity (ERSNA) will be discussed in the following sections of this chapter. 
The sympathetic preganglionic neurons that give rise to the renal nerves exit the 
spinal cord and synapse in the paravertebral ganglia (T6-L4) and the aorticorenal, celiac 
and the superior mesenteric prevertebral ganglia with significant interspecies variability 
(38, 148). The sympathetic postganglionic fibers exit their respective ganglia, course 
along the renal artery and renal vein, and enter the kidney via the hilum. Within the 
kidney, sympathetic fibers innervate multiple structures. The most densely innervated of 
these structures include the afferent and efferent glomerular arterioles, the 
juxtaglomerular cells and renal tubular epithelial cells (82). 
 Sympathetic innervation of the renal resistance vessels has been well 
characterized. Specifically, efferent renal nerves have been shown to innervate the 
vascular smooth muscle cells of both the afferent and efferent arterioles as well as the 
interlobar, interlobular and arcuate arteries. Efferent renal nerves also directly innervate 
the juxtaglomerular (JG) cells that account for the majority of renin production in the 
body. Lastly, the entire renal tubular system is innervated by sympathetic fibers although 
the most densely innervated segment is the proximal tubule. 
  
Functions of the efferent renal nerves 
 As with all sympathetic nerves, the primary neurotransmitter of the renal 
sympathetic postganglionic nerves is norepinephrine (NE). In addition, there is evidence 
that these neurons also release a number of cotransmitters such as dopamine, nitric oxide, 
neuropeptide Y, vasoactive intestinal peptide and adenosine. While it is likely that these 
neurotransmitters play some role in the sympathetic control of renal function, the 
importance of such cotransmitters in the kidney is largely unknown. Therefore, this 
section will focus on the role of NE and its receptors on renal function. 
As previously mentioned, the three structures that are primarily innervated by 
efferent renal nerves are the renal resistance vessels, JG cells and renal tubular epithelial 
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cells. As a result, the three primary physiological functions influenced by ERSNA are 
renal vascular resistance, renin release and renal sodium reabsorption. Changes in all of 
these parameters follow stimulation of the target cells by NE; however, the adrenergic 
receptors (ARs) and intracellular signaling pathways involved are quite different.  
The JG cells express the β1AR on their plasma membrane. NE released from 
sympathetic nerve terminals binds to the β1AR leading to activation of adenylyl cyclase 
resulting in increased levels of intracellular cyclic adenosine monophosphate (cAMP). 
The cAMP signaling pathway in turn promotes increased production and release of renin 
from the JG cells (59, 81). The renal resistance vessels are stimulated by efferent renal 
nerves primarily via the α1AAR. Stimulation of the α1AAR results in phospholipase C 
signaling and increased intracellular Ca
2+
 leading to contraction of the smooth muscle 
cells and thus vasoconstriction (82). Sympathetic stimulation of the tubular epithelial 
cells occurs primarily through α1BAR which, through mitogen activated protein kinase 
(MAPK) signaling, results in increased apical expression of the sodium/hydrogen 
exchanger (NHE3). Additionally, through Ca
2+/calcineurin signaling, α1BAR activation 
results in increased activity of the sodium potassium ATPase (Na
+
/K
+
ATPase) on the 
basolateral membrane. Increased expression of NHE3 and activity of Na
+
/K
+
ATPase 
facilitate the reabsorption of sodium from the tubular lumen into the blood (82). 
It is well accepted that renin release, renal vascular resistance and sodium 
reabsorption are influenced by ERSNA; however, there is some debate as to the 
importance of neural control of these parameters under normal physiological conditions. 
It has been shown that electrical stimulation of the renal nerves caused frequency-
dependent activation of these functions (38). Increased release of renin occurred at a 
relatively low frequency of renal nerve stimulation. At slightly higher frequency of 
stimulation, sodium reabsorption was increased. It was not until a relatively high 
frequency of stimulation that renal blood flow (RBF) was decreased. It has been 
suggested that because the frequency of stimulation required to evoke reductions in RBF 
were so high in this experiment, ERSNA is likely not a factor in every day control of 
RBF. This assertion was recently challenged by Yoshimoto et al., who continuously 
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recorded renal nerve activity and RBF in conscious, freely moving rats (179). The results 
of this study showed that changes in RBF that occurred during normal changes in 
behavioral state were accompanied by changes in RSNA. Malpas et al., performed a 
similar study in rabbits and showed that while the presence or absence of renal nerves 
does not alter 24 hour averaged RBF, RSNA does influence episodic changes in RBF 
(11). Taken together, the results of these two studies suggest that RSNA can indeed 
influence RBF under normal physiological conditions.  
It is also important to note that while ERSNA has been shown to influence renin 
release, sodium reabsorption and renal vascular resistance, there are a number of 
redundant control mechanisms that influence all three of these parameters. In fact, when 
the renal nerves are removed by RDNX most studies have found that these parameters 
remain, on average, within normal physiological ranges (11, 77, 78). It is therefore likely 
that chronic changes in these parameters would be observed following RDNX only in 
situations of inappropriately high ERSNA. 
 
Acute regulation of efferent renal nerve activity 
 A significant amount of work has gone into elucidating the mechanisms by which 
ERSNA is controlled. By in large, these have been acute experiments performed in 
anesthetized animals. While the results of such experiments may not relate to the 
mechanisms underlying chronic regulation of ERSNA, these important experiments have 
revealed a number of factors that can influence ERSNA acutely. 
 As discussed earlier, there are many regions of the brain that are involved in the 
regulation of sympathetic outflow. With regard to the renal nerves, it is thought that the 
RVLM is primary controller of ERSNA (57). The RVLM receives excitatory input from 
the PVN and inhibitory input from the NTS. In turn, the PVN and NTS receive various 
inputs from sensory pathways creating numerous possible mechanisms for the regulation 
of ERSNA. 
Baro-, chemo- and cardiopulmonary reflexes: There are many neural and humoral 
factors that can influence the firing of the central sympathomodulatory pathways, the best 
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studies of which is the baroreceptor reflex (baroreflex). Stretch receptors in the aortic 
arch and carotid sinuses, called baroreceptors, become activated as increased AP causes 
stretching of the aorta and carotid arteries (64). When the baroreceptors are activated, 
they send signals back to the brain via afferent nerves exciting neurons in the NTS. In 
turn, the NTS sends excitatory input into the CVLM which increases inhibitory input to 
the RVLM and ultimately reduces sympathetic outflow to various targets of 
cardiovascular importance including the kidney (34). Therefore, increases in AP, sensed 
by the aortic and carotid baroreceptors, result in a suppression of ERSNA (14). While this 
has been demonstrated repeatedly in acute experiments, the role of baroreflex control of 
ERSNA chronically has been shown to be minimal. In fact removal of baroreceptor input 
by sinoaortic denervation (SAD) has been shown to cause elevations in ERSNA and AP; 
however, these parameters return to normal levels within days of surgery suggesting that 
the baroreflex plays a role in short term rather than long term control of ERSNA (73). In 
addition to baroreflex control of ERSNA, the low pressure cardiopulmonary receptors 
and peripheral arterial chemoreceptors have been shown to regulate the efferent renal 
nerves through their input into the same regulatory regions of the brain (70, 169). 
Visceral reflexes: Many acute studies have demonstrated the existence of reflex 
arcs that originate in various organs and reflexively regulate ERSNA. Of these visceral 
reflexes, the most well studied is the so called reno-renal reflex in which afferent renal 
nerve activity (ARNA) has been shown to inhibit ERSNA (52). In addition, 
osmosensitive afferents in the hepatoportal circulation have been shown to influence 
ERSNA (129). There is even evidence for a spleno-renal reflex (61). Taken together, 
these studies and many more demonstrate the vast neural networks that are involved in 
the regulation of ERSNA; however, it should be noted that these are acute studies and the 
role of these various neural inputs in the chronic regulation of ERSNA is not known.  
Plasma and CSF osmolality: Another factor that can contribute to the regulation 
of ERSNA is the ionic composition of the blood and cerebrospinal fluid (CSF). Most 
studies have shown that infusion of hypertonic saline into the CSF 
(intracerebroventricular; i.c.v.) causes a decrease in ERSNA, although some studies have 
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shown increases in ERSNA with i.c.v. hypertonic saline, suggesting that there are regions 
of the central sympathoregulatory circuit that are sodium-sensitive (71, 177). 
Additionally, intravenous infusion of hypertonic saline has been shown to alter ERSNA 
(10). Taken together, these studies suggest that there are osmosensitive regions in the 
brain that alter SNA to the kidneys. Moreover, the fact that increases in both plasma 
osmolality and CSF osmolality increase ERSNA suggests that the osmosensitive 
region(s) of the brain likely lie outside of the blood brain barrier (BBB). In fact, both the 
SFO and OVLT, which lack a BBB have been shown to be osmosensitive making them 
the likely sensory regions that respond to changes in plasma or CSF osmolality (6, 17). In 
addition, to plasma or CSF osmolality, the SFO and OVLT are thought to respond to 
various circulating factors including angiotensin II (AngII), aldosterone and leptin. The 
effect of these hormones on ERSNA will be discussed in the next section as they have 
been shown to influence ERSNA both acutely and chronically. 
Stress: It should also be noted that various types of stressors, such as air jet stress 
and cold water stress, have been shown to activate the renal nerves (37, 84). While many 
studies have shown acute responses of ERSNA to these stressors, the role that stress 
plays in chronic elevations in SNA and AP is largely unknown at this point, although 
much work is currently being done to investigate this possible link. 
 
Chronic regulation of ERSNA 
 Acute experiments have uncovered many factors that can regulate ERSNA, but 
when considering the role of renal nerves in chronic HTN, it is more important to 
determine what factors contribute to the long term regulation of renal sympathetic 
outflow. While this is a much more difficult task, a number of important studies have 
expanded our understanding of the long term regulators of ERSNA. Using direct or 
indirect indices of ERNSA, a number of hypertensive stimuli have also been shown to 
cause long term changes in renal nerve activity. In this section I will review what is 
known about the roles of AngII, aldosterone and leptin in chronic regulation of ERSNA.  
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Angiotensin II: The functional end product of the renin-angiotensin system, 
AngII, is known to have many prohypertensive properties as it causes vasoconstriction, 
sodium retention and increased production of the salt retaining hormone, aldosterone. 
Additionally, AngII receptors have been identified in the CVOs of the brain and 
electrolytic lesioning of both the SFO and OVLT have been shown to attenuate HTN 
produced by chronic infusion of exogenous AngII (65, 163). Interestingly, renal nerve 
activity has been shown to inhibited or enhanced in a species-dependent manner during 
chronic AngII infusion. Using direct nerve recording techniques in chronically 
instrumented rats, our lab has shown that AngII causes a reduction in ERSNA (178). 
Similar results have been shown in rabbits receiving chronic AngII infusion (12). Renal 
NE overflow, an index of ERSNA, was also shown to be decreased with chronic AngII 
infusion in dogs (24). Denervation studies have shown mixed results as to the ability of 
RDNX to reduce AP in the AngII induced HTN (20, 66, 91). While these data, when 
considered together, constitute a rather unclear story, it is undeniable that AngII can 
influence the activity of the renal nerves chronically, although the direction and 
magnitude of this regulation may be model-dependent.  
Aldosterone and leptin: In addition to AngII, aldosterone and leptin have been 
shown to act in the CNS and are both associated with neurogenic HTN (31, 51). 
Moreover, denervation studies have repeatedly shown that RDNX attenuates HTN 
associated with these hormones, suggesting that aldosterone and leptin can act though the 
renal nerves to increase AP (60, 77). Receptors for aldosterone and leptin receptors have 
been identified in various regions of the brain including the hypothalamus and it is likely 
that these sympathoexcitatory substances act through many of the same central pathways 
as AngII (60, 106). 
Much of what is known about the chronic regulation of ERSNA comes from 
studies in which naturally occurring stimuli are given in excess exogenously. While these 
studies are useful in establishing proof of concept, they do not provide solid evidence for 
the mechanisms involved in the naturally occurring over activity of renal nerves. A 
significant amount of work is needed to address this point. 
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1.3 Afferent renal nerves 
 
Anatomy of the afferent renal nerves 
 The cell bodies of the sensory (afferent) neurons of kidneys have been found in 
the dorsal root ganglia (DRG) at spinal levels from T8 to L4 (Fig. 1) with interspecies 
variability (2, 104, 139, 170). The peripheral axons of these neurons course out of the 
DRG, join the renal nerve bundles near the renal artery and vein, and enter the kidney via 
the hilum. Inside the kidney primary afferent renal nerves innervate, almost exclusively, 
the wall of the renal pelvis, although a small number of renal afferent fibers have been 
shown to innervate the interlobar and arcuate arteries and, to a lesser extent, the 
interlobular arteries and afferent arterioles (45, 116).  
The central axons of the DRG cells course through the dorsal roots and into the 
dorsal horn where they synapse onto second order neurons. Sensory information from the 
kidneys then ascends via the spinoreticular and spinothalamic tracts (3-5). It should be 
noted that a very small portion of afferent renal nerves have been shown to project 
monosynaptically to the medulla (94, 174). Fos labeling in the brain following afferent 
renal nerve stimulation has revealed increased activity in the OVLT, SFO, MnPO, PVN, 
NTS, supraoptic nucleus (SON) and many other nuclei (147). It is through input into this 
vast network of autonomic regulatory regions of the brain that ARNA is thought to 
influence various homeostatic processes. 
Primary Afferent fibers are often classified into various fiber types as defined by 
fiber diameter, conduction velocity and myelination state. The renal primary afferents 
have been shown to be mostly (75-80%) slow conducting unmyelinated C-fibers with a 
much smaller population (~20%) of faster conducting thinly myelinated A-δ fibers (92, 
93, 128). Additionally, a very small population (~5%) of rapidly conducting (12-32 m/s) 
myelinated afferent renal nerve fibers has been reported. 
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Functions of the afferent renal nerves 
 Renal Pain: The kidneys, like many visceral organs, relay many different sensory 
modalities to the central nervous system and therefore activation of afferent renal nerves 
results in many different functional outcomes. Perhaps the most intuitive of these is the 
sensation of pain resulting from renal injury. Indeed damage to the kidneys resulting from 
insults such as kidney disease and kidney stones causes a great deal of pain to the patient. 
This sensation of pain results from afferent renal pathways converging with somatic 
nociceptive pathways from the flank and abdomen within the spinothalamic tract of 
spinal cord (3). Noxious stimuli in the kidney therefore are interpreted by the brain as 
flank or abdominal pain. This type of referred pain is common with visceral organs and 
exists to alert the brain of internal problems.  
 Modulation of cardiovascular function: In addition to the sensation of renal pain, 
activation of afferent renal nerves has been shown to have a number of various autonomic 
consequences. Many studies have shown that activation of afferent renal nerves results in 
robust alterations in cardiovascular function. Specifically, most studies have found that 
increases in ARNA are associated with increases in mean arterial pressure (MAP) and 
heart rate (HR) as well as increases in regional and total peripheral vascular resistance 
(TPR), suggesting the presence of sympathoexcitatory afferent renal nerves (7, 44, 150). 
Interestingly, these same types of studies, when performed in rabbits, typically result in 
the opposite effects (109). That is stimulation of afferent renal nerves in the rabbit 
generally results in a decrease in MAP, HR and TPR, suggesting the presence of 
sympathoinhibitory afferent renal nerves in the rabbit. 
 Reno-renal reflex: While stimulation of afferent renal nerves typically causes 
increases in SNA to various cardiovascular targets, it has been consistently shown that it 
also results in a suppression of SNA to the kidneys (29, 180). This so called “renorenal 
reflex” has been extensively studied by a number of labs throughout the past three 
decades. In short, when activated by a number of different stimuli, afferent renal nerves 
act to inhibit ERSNA and promote natriuresis and diuresis. While this reflex has been 
shown extensively in acute anesthetized preparations and, to a lesser extent, in acute 
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experiments in conscious animals, its role in the long term regulation of ERSNA and salt 
and water homeostasis is more controversial. It has been proposed that this inhibitory 
renorenal reflex is important in maintaining sodium and water homeostasis in situations 
of dietary sodium loading (82), although my own work (presented in chapter three) 
directly contradicts this theory. 
 Release of vasopressin and oxytocin: As mentioned earlier, renal afferent 
signaling results in the excitation of neurons in a number of different regions of the brain. 
Among these is the SON, a part of the brain that is critical for the release of the hormones 
vasopressin and oxytocin (35). Moreover, it has been shown that stimulation of afferent 
renal nerves results in increased plasma vasopressin levels (25, 144). Although less well 
studied, increased ARNA has also been shown to increase levels of oxytocin in the blood 
(144). Since vasopressin acts on the kidney to promote water retention, it makes sense 
that signals from the kidney can stimulate its release. Moreover, misregulation of this 
kidney-SON axis may explain some forms of HTN that have been linked to both 
increased ARNA and vasopressin release. This will be discussed in relation to the 
deoxycorticosterone acetate (DOCA)-salt model of HTN in chapter three. 
 
Acute regulation of afferent renal nerve activity 
Acute experiments have shown that afferent renal nerves respond to many 
different stimuli. In general this has led to the classification of afferent renal nerves into 
three functional categories: mechanosensitive, chemosensitive or nociceptive.  
Mechanosensitive: Because the wall of the renal pelvis to densely innervated by 
afferent renal nerves(45), it is not surprising that changes within the pelvis can stimulate 
these nerves. One such intrapelvic stimulus is mechanical stretch. It has been shown that 
increases in renal pelvic pressure result in increases in ARNA. Forceful pressurization of 
the renal pelvis, occlusion of the ureter, and increases in urine flow rate following acute 
volume loading or administration of diuretics have all been shown to induce increases in 
ARNA (5, 53, 99). Other mechanical stimuli have been shown to increase activity of 
afferent renal nerves as well. Among these are increased renal arterial, venous or 
15 
 
interstitial pressure (124). While these responses have been clearly shown, it is unclear 
whether these stimuli act on the same population of afferent fibers that are stimulated by 
increased pelvic pressure, or if a separate population of fibers is responsible for the 
response.  
Chemosensitive: In addition to the presence of mechanosensitive afferent renal 
nerves, it has been repeatedly demonstrated that afferent renal nerves respond to chemical 
stimuli within the kidney.  Among the stimuli most studied are adenosine, bradykinin, 
substance P and prostaglandin E2. Infusion of these compounds into the renal pelvis or 
renal artery has been shown to elicit increases in ARNA (87, 96, 111, 146). Some studies 
have also shown that increases in pelvic sodium concentration by intrapelvic infusion of 
hypertonic saline can lead to activation of afferent renal nerves (182). Lastly, renal 
ischemia caused by acute reductions in RBF is known to stimulate ARNA (110).  
 Nociceptors: As mentioned earlier, some of the afferent neural pathways from the 
kidneys have been shown to ascend the spinal cord through the spinothalamic tract (3). 
Moreover, neurons in this pathway are responsive to both renal and cutaneous noxious 
stimuli. These observations demonstrate the basis for referred renal pain that is 
experienced in renal disease and in the presence of kidney stones.  
 Although afferent renal nerves can be classified into three functional categories, it 
should be noted that there is some evidence of mechanistic overlap. Single afferent renal 
neurons likely respond to multiple types of stimuli. For example, both mechanical stretch 
and intrapelvic substance P administration have been shown to activate a single afferent 
renal nerve unit (111).   
 
Chronic regulation of afferent renal nerve activity 
While acute stimuli of ARNA have been fairly well studied, it is less clear what 
may regulate the activity of these nerves chronically. There is, however, a significant 
body of evidence suggesting that these nerves may be perpetually overactive in the 
setting of chronic kidney disease (CKD). This hypothesis is derived from a number of 
pieces of evidence. First, as discussed earlier, acute stimulation of afferent renal nerves 
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has been shown to increase SNA and AP in many studies. Second, many patients with 
advanced CDK or end-stage renal disease (ESRD) have elevated levels of muscle SNA 
(15, 127). Lastly, it has been reported that when these hypertensive ESRD patients 
receive bilateral, but not unilateral kidney transplants, muscle SNA and AP are reduced 
(63).  
A possible role of renal pathology in chronic overactivity of afferent renal nerves 
is supported by studies in which unilateral denervation attenuates HTN induced by some 
type of insult to the denervated kidney. In this regard, Katholi e. al., showed that HTN 
induced by renal artery stenosis is partially reversed by denervation of the ischemic 
kidney (88, 89). Moreover, they showed that this chronic hyperactivity of the afferent 
renal nerves is dependent on adenosine signaling in the kidney (86). Similar studies by 
Campese et al., showed that renal damage induced by injection of phenol into the kidney 
results in HTN that is prevented by ipsilateral but not contralateral removal renal afferent 
input (21). Taken together, these studies suggest that chronic renal pathology can cause 
afferent renal nerve dependent HTN. 
Data from these studies in people and animals provide convincing evidence that 
afferent renal nerves are a link between kidney disease and HTN; however, the 
mechanisms by which CKD may lead to chronic activation of afferent renal nerves 
remain unclear. One possibility that has been proposed is that inflammatory signals in the 
kidneys, induced by renal damage, stimulate afferent renal nerves. Indeed significant 
infiltration of immune cells into the kidneys has been shown repeatedly in various models 
of HTN (62, 141). Moreover, it has been shown that some cytokines, which are released 
from inflammatory immune cells, can activate sensory fibers (27). Taken together, these 
observations raise the possibility that the renal damage associated with CKD leads to 
infiltration of inflammatory immune cells into the kidney which release cytokines that 
then act on sympathoexcitatory afferent renal nerves to drive HTN.  
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1.4 Differential role of afferent and efferent renal nerves in 
hypertension 
  
The antihypertensive effect of RDNX has been extensively documented in various animal 
models of HTN and, although somewhat controversial, in human hypertensives as well 
(13, 38). While the results of such studies highlight the promise of RDNX as an effective 
treatment modality, there are currently many questions surrounding the mechanisms 
underlying the antihypertensive effect of RDNX. At the forefront of these questions is 
whether the therapeutic effects of RDNX are due to ablation of afferent or efferent renal 
nerves. This distinction is important with regard to optimizing the efficacy of RDNX or 
developing more specific ablation techniques in order to minimize possible side effects. 
While this treatment was originally developed with the intent of disrupting overactive 
ERSNA which could contribute to HTN by increasing renal vascular resistance, renin 
release or tubular sodium and water reabsorption; clinical evidence suggests that ablation 
of afferent renal nerves has observable functional consequences. Namely, RDNX has 
been shown to decrease: plasma glucose, muscle sympathetic nerve activity, incidence of 
sleep apnea and cardiac arrhythmias, suggesting that RDNX causes alterations in 
sympathetic outflow to non-renal targets (67, 149, 171). These observations indicate the 
further possibility that RDNX reduces AP by reducing sympathetic outflow to targets of 
cardiovascular importance such as the splanchnic vascular bed, skeletal muscle vascular 
bed or kidneys. In this section, I will review the preclinical studies that have used various 
denervation techniques to explore the differential role of afferent and efferent renal 
nerves in the antihypertensive effect of RDNX.   
 
Dorsal rhizotomy 
In 1985, Brody et al., showed that surgical sectioning of the dorsal roots (dorsal 
rhizotomy) at spinal levels T10-L1 in order to produce a selective ablation of afferent 
renal nerves (105). Indeed this technique permanently eliminates the majority of renal 
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afferent input into the spinal cord; however, because a large number of non-renal afferent 
pathways enter the spinal cord at these levels as well, this technique is not selective for 
renal afferent neurons (26, 103, 120). Moreover, this technique fails to ablate the small 
portion of afferent renal nerve fibers that enter the spinal cord above T9 and below L1. 
Despite these limitations, studies using DRX have provided significant insight into the 
possible physiological roles of afferent renal nerves.  
Removal of renal afferent input by DRX in normotensive rats has been shown to 
result in salt-sensitivity of blood pressure (97). That is, DRX rats become hypertensive 
when fed a high salt diet as compared to sham operated rats. Moreover, these rats have 
been shown to retain sodium and water compared to sham rats, indicating elevated 
ERSNA, i.e. diminished renorenal reflex. These results have been interpreted to mean 
that high dietary consumption of sodium causes an increase in ARNA which then 
suppresses ERSNA leading to natriuresis and diuresis to maintain sodium balance. DRX 
rats therefore become hypertensive when fed a high sodium diet because they are unable 
to suppress ERSNA leading to inappropriately high sodium and water retention and, as a 
result, increased blood volume. This finding, however, is complicated by the non-
selective nature of RDX and is directly challenged by my own results presented in 
chapter three. 
 
Systemic administration of capsaicin 
Systemic administration of the transient receptor potential vanilloid 1 (TRPV1) 
receptor agonist, capsaicin to neonatal rata pups has been used for decades to ablate 
sensory fibers throughout the body. While this whole body deafferentation has largely 
been used to study sensory pathways involved in pain, Wang et al., have used this 
technique extensively to study the role of capsaicin sensitive afferent fibers in 
cardiovascular regulation. As is true with RDX, these studies have demonstrated that high 
sodium intake causes marked HTN in rats subjected to systemic capsaicin as neonatal 
pups as compared to vehicle treated rats (164). Again, these results have been interpreted 
to suggest that ablation of sympathoinhibitory afferent renal nerves leads to 
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inappropriately elevated ERSNA during high salt intake. This assertion will also be 
challenged in chapter three. 
 
Investigations into the role of afferent renal nerves in animal models of HTN 
In the 1980s and ‘90s, there were a number of experiments that attempted to 
assess the role of afferent renal nerves in HTN using complete RDNX or DRX. These 
studies, while imperfect in the use of nonselective denervation techniques, established a 
possible role of afferent renal nerves in various forms of HTN.  
Among the most studied models of HTN are the Goldblatt models of renovascular 
HTN. In these models, HTN develops secondary to renal artery stenosis which is created 
by placing a clip around the renal artery reducing RBF. Goldblatt HTN is typically 
induced by clipping one (2 kidney, 1 clip; 2K1C) or both (2 kidney, 2 clip; 2K2C) 
kidneys, or by removing one kidney and clipping the remaining kidney (1 kidney, 1 clip; 
1K1C). Interestingly, denervation of the clipped kidney partially reverses 2K1C HTN, 
whereas denervation of the unclipped kidney has no effect on 2K1C HTN (88). Likewise, 
it has been shown that RDNX partially attenuates 1K1C HTN (89, 130). Because the 
stimulus for HTN in these models clearly comes from the clipped kidney, these results 
were taken to suggest that activation of afferent renal nerves was responsible, in part, for 
the HTN induced by renal artery stenosis. Later studies supported this conclusion more 
directly by showing that DRX also attenuates 2K2C and 1K1C HTN (167, 173). 
In addition to the Goldblatt models, DRX has been shown to attenuate a number 
of other models of HTN. Campese et al., have extensively characterized the phenol renal 
injury model of HTN in which phenol is injected directly into the cortex of one kidney. 
The resulting renal injury leads to increased SNA and HTN, both of which are prevented 
by DRX, suggesting that renal injury leads to afferent renal nerve-dependent increases in 
SNA and AP (21, 22). Additionally, cyclosporine A-induced HTN in attenuated by DRX 
suggesting that the HTN associated with post-renal transplant cyclosporine treatment is 
caused by activation of ARNs (181). 
20 
 
It is important to note that DRX has failed to attenuate a number of other models 
of HTN. Most importantly, DRX did not attenuate the development of HTN in the 
spontaneously hypertensive rat (SHR) (175). This is a critical finding since this 
genetically spontaneous form of HTN is considered to be one of the more relevant 
models of human HTN. Additionally, HTN induced by infusion of NE into the renal 
artery or by wrapping and compressing one kidney with suture (renal wrap model) is not 
attenuated by DRX (80, 133). Taken together, these studies suggest that ARNs likely do 
not play a role in all forms of human HTN.   
  
1.5 Thesis overview 
 
While it has been shown that, at least in some people, RDNX can lower AP, it remains 
unclear whether this effect is due to ablation of afferent or efferent renal nerves. The 
importance of this question has been highlighted by the failure of a recent clinical trial of 
RDNX. In order to address this question, I have 1) established a model of HTN in which 
RDNX lowers AP, 2) developed a technique to selectively ablate afferent renal nerves, 
and 3) used this technique to test the central hypothesis that the antihypertensive effect of 
RDNX is due to ablation of afferent rather than efferent renal nerves (Figure 3). 
The first of these points is addressed in chapter two. This chapter contains data 
from experiments that establish a genetic model of salt-sensitive HTN, the Dahl salt-
sensitive (S) rat, as a model in which RDNX reduced AP. This project also established 
that, in addition to the renal nerves, the splanchnic sympathetic nerves are important in 
the maintenance of HTN in this model. Moreover, the antihypertensive effect of both 
RDNX and celiac ganglionectomy (CGX) to remove splanchnic sympathetic innervation, 
were unrelated to salt and water unloading. The results of this study showed the potential 
of targeting at multiple sympathetic end organs for the treatment of HTN. 
Chapter three focuses on the development and validation of a novel method for 
selective ablation of afferent renal nerves, termed renal-CAP treatment. We showed that 
1) renal-CAP treatment causes loss of afferent, but not efferent neural markers from 
21 
 
kidneys as assessed by immunohistochemistry and tissue assays, 2) renal-CAP treatment 
causes loss of afferent renal nerve functionality as assess by physiological responses to 
pharmacological activation of afferent renal nerves, 3) afferent renal nerves do not play a 
significant role in cardiovascular or sodium/water homeostasis during chronic dietary 
sodium loading and 4) the antihypertensive effect of RDNX in the DOCA-salt model is 
due to ablation of afferent renal nerves. 
Having established the Dahl S rat as model HTN in which RDNX lowers AP, 
chapter four discusses data from a study in which we tested the hypothesis that the 
antihypertensive effect of RDNX in the Dahl S rat is due to ablation of afferent renal 
nerves. In this study we showed that the antihypertensive effect of RDNX in the Dahl S 
rat is identical whether it is done after 3 weeks of high salt (when MAP is ~140 mmHg) 
or whether it is done after 9 weeks of high salt (when MAP is ~170 mmHg).  Moreover, 
we showed that, while RDNX lowered MAP ~10 mmHg compared to SHAM, renal-CAP 
treatment had absolutely no effect on AP. Taken together, these results suggest that the 
antihypertensive effect of RDNX in the Dahl S rat is not dependent on duration of high 
salt feeding or pretreatment blood pressure and that the antihypertensive effect of RDNX 
in this model is not due to ablation of afferent renal nerves.  
In the final chapter, I will summarize all of these findings and lay out the 
significance of this work. This chapter will highlight the importance of the work 
presented and discuss how our findings not only inform the basic science aspect of HTN, 
but how they may impact the future of HTN treatment. 
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Figure 1. Gross anatomy of the renal nerves. Renal afferent pathways are depicted on 
the left. The cell bodies of renal primary afferent neurons are located in the dorsal root 
ganglia (DRG) at spinal levels T8-L4. These neurons have peripheral axons, which 
innvervate primarily the renal pelvic wall, and central axons, which synapse on secondary 
afferent neurons in the dorsal horn of the spinal cord. Renal efferent pathways are 
depicted on the right. Presympathetic neurons in the brain synapse onto sympathetic 
preganglionic neurons in the intermediolater cell column (IML) of the spinal cord. These 
neurons in turn have axons that synapse onto sympathetic post ganglionic neurons in the 
paravertebral ganglia (T6-L4) and the celiac, superior mesenteric and aorticorenal 
prevertebral ganglia. The axons of these postganlionic neurons course along the renal 
artery and vein, into the kidney and innervate primarily the glomerular arterioles, renal 
tubules and juxtaglomerular (JG) cells. 
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Figure 2. Sympathoregulatory brain regions involved in control of efferent 
sympathetic renal nerve activity. SFO = subfornical organ, MnPO = median preoptic 
nucleus, OVLT = organum vasculosum of the lamina terminalis, PVN = paraventricular 
nucleus, NTS = nucleus of the solitary tract, RVLM = rostral ventrolateral medulla. 
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Figure 3. Hypothetical model. Chronic stimuli such as kidney disease, renal 
inflammation and renal ischemia cause increases in afferent renal nerve activity (ARNA). 
In turn, this drives sympathetic outflow to non-renal targets causing an increase in 
peripheral resistance and thus arterial pressure. Chronic increases in arterial pressure lead 
to feed back to cause additional insult to the kidney further driving ARNA. 
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2.1 Summary 
 
The sympathetic nervous system plays an important role in some forms of human 
hypertension as well as the Dahl salt-sensitive rat model of hypertension; however, the 
sympathetic targets involved remain unclear. To address this, we examined the role of the 
renal and splanchnic sympathetic nerves in Dahl hypertension by performing either sham 
surgery (n = 10) or targeted sympathetic ablation of the renal nerves (renal denervation, n 
= 11), the splanchnic nerves (celiac ganglionectomy, n = 11) or both renal and splanchnic 
nerves (n = 11) in hypertensive Dahl rats.  Mean arterial pressure increased from ~120 
mmHg while on a 0.1% sodium chloride diet, to ~140 mmHg after being fed a 4.0% 
sodium chloride diet for three weeks. At that point rats underwent sham or targeted 
sympathetic ablation. Four weeks after treatment, mean arterial pressure was lower in 
renal denervated (150.4 ± 10.4) and celiac ganglionectomized (147.0 ± 6.1) rats 
compared to sham rats (165.0 ± 3.7), and even lower in rats that underwent both ablations 
(128.4 ± 6.6). There were no differences in heart rate or fluid balance between sham and 
renal denervated rats; however, rats that underwent either celiac ganglionectomy or both 
ablations exhibited marked tachycardia as well as sodium and water retention following 
treatment. These data suggest that targeted sympathetic ablation is an effective treatment 
for established hypertension in the Dahl rat and that the kidneys and the splanchnic 
vascular bed are both independently important targets of the sympathetic nervous system 
in this model. 
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2.2 Introduction 
 
Hypertension is the leading risk factor for death worldwide (108), yet the underlying 
causes are poorly understood as evidenced by the staggering number of uncontrolled 
cases of hypertension (33, 40, 131, 136). Recent studies have shown that catheter-based 
renal nerve ablation results in a sustained reduction of arterial pressure in drug resistant 
hypertensives, suggesting that targeted sympathetic ablation may be an effective 
treatment for hypertension that avoids the side effects of globally acting sympatholytic 
drugs (100, 152, 153). 
While the kidneys appear to be sympathetic targets in some forms of 
hypertension, other vascular beds, such as the splanchnic circulation, are also likely 
important as evidenced by the ability of splanchnic nerve stimulation to increase arterial 
pressure (102) and surgical splanchnic sympathectomy to attenuate drug resistant 
hypertension in humans (56, 145).  Additionally, we have shown that the splanchnic, but 
not renal nerves contribute to the pathophysiology of angiotensin II-salt (AngII-salt) 
hypertension (91). Together, these findings suggest that renal nerve ablation may be 
effective in some, but not all, forms of hypertension and that targeted sympathetic 
ablation of non-renal vascular beds may be an effective strategy for the treatment of 
hypertension in some individuals.  
With that in mind, the present study compared the effects of renal and splanchnic 
nerve ablation on arterial pressure and body fluid balance in a well-accepted and widely 
studied   genetic model of neurogenic hypertension - the   Dahl salt-sensitive (Dahl S) rat. 
Similar to a significant fraction of humans with essential hypertension, the Dahl S 
rat becomes hypertensive when fed a high salt diet, has increased sympathetic activity 
(19, 50, 54, 55, 117, 155) and has increased renal and splanchnic vascular resistance (16). 
Although renal nerve ablation has been consistently reported to have no effect on the 
development of Dahl S hypertension (75, 126, 132, 176), the ability of renal nerve 
ablation to reverse hypertension in this model not been reported. This is an important 
distinction with respect to the development of new therapies, which for the foreseeable 
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future will focus on the treatment rather than prevention of hypertension. To our 
knowledge, the effect of splanchnic nerve ablation on either the developmental or 
maintenance phase of Dahl S hypertension has not been reported.  
The present study was designed to address the following questions. First, once 
hypertension is initiated does renal nerve ablation decrease arterial pressure in the Dahl S 
rat? If so, is this response due to increased renal excretion of sodium and water? Second, 
does ablation of sympathetic nerves innervating the splanchnic vascular bed decrease 
arterial pressure in the Dahl S rat and, if so, how does that response compare to renal 
nerve ablation? Third, is combined regional sympathectomy more effective in lowering 
arterial pressure than denervation of a single target? 
  
2.3 Methods 
 
Animals and General Procedures 
Male Dahl S rats were purchased from Charles River Laboratories (Wilmington, 
MA) and housed in pairs in a temperature and light controlled room until the beginning 
of the study, at which time they were 64-70 days old and 250-340g.  The rats were 
allowed access to standard rat chow and distilled water ad libitum during this pre-
experimental period. All procedures were approved by the University of Minnesota 
Animal Care and Use Committee and were conducted in accordance with the institutional 
and National Institutes of Health guidelines. For all surgeries, rats were anesthetized with 
2.0% isoflurane.  Atropine sulfate (0.4 mg/kg, IP) and gentamicin sulfate (10 mg/kg, IM) 
were administered prior to surgery.  For three days following surgery, buprenorphine 
(0.015 mg, SQ) was given twice per day and the drinking water was supplemented with 
amoxicillin (1 mg/ml).   
 
Experimental Protocol 
The timeline for the experimental protocol is shown in Figure 1. Rats were placed 
on a low salt diet (0.1% NaCl; Research Diets, New Brunswick, NJ) and instrumented 
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with radio telemeters (model TA11PA-C40, DSI, Intl. St. Paul, MN) for monitoring of 
mean arterial pressure (MAP) and heart rate (HR) as previously described (162). After a 
7-day recovery period, rats were individually housed in metabolic cages (Techniplast 
3701M001, Buguggiate, Italy) and allowed to acclimate for four days. Three days of 
baseline data were then collected (see below for details) and rats were placed on a high 
salt diet (4.0% NaCl; Research Diets) for the remainder of the protocol. After 21 days of 
high salt intake, rats were anesthetized with isoflurane and, via a midline approach, 
subjected to a sham (SHAM; n = 10), renal denervation (RDNX; n = 11), celiac 
ganglionectomy (CGX; n = 11) or combined renal denervation and celiac 
ganglionectomy (RDNX-CGX; n = 11) procedure.  SHAM, RDNX and CGX procedures 
were performed as previously described (76, 107) and the combined RDNX-CGX was 
achieved by performing the RDNX and CGX in single procedure. Rats were returned to 
their cages and monitored for an additional 4 weeks. Upon completion of the study, rats 
were anesthetized with isoflurane and the duodenum, liver, spleen and both kidneys of 
each rat were harvested, weighed, immediately frozen with liquid nitrogen and stored at 
−80 °C until they were assayed for tissue norepinephrine content as previously described 
(107).   
 
Daily Measurements 
The transmitter signal was monitored by a receiver (Data Sciences, model RPC-1) 
mounted on the side of the metabolic cage and connected to a Data Exchange Matrix 
(Data Sciences, Int). The arterial pressure signal was sampled at 500 samples/second for 
10 seconds every 4 minutes using commercially available software (Data Sciences, Int.). 
HR was determined from the arterial pressure profile using the same software. 24 hour 
(24h) averages of MAP and HR were determined and plotted for each day of the study. 
24h food intake, water intake and urine output were measured gravimetrically. 24h 
sodium intake was calculated by multiplying food intake (grams) and sodium content of 
the diet (0.1% NaCl = 0.01711 mmol Na+/g food; 4.0% NaCl = 0.6844 mmol Na+/g 
food). 24h sodium excretion was calculated by multiplying 24h urine output (ml) and 
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urinary sodium concentration (mmol Na+/ml), which was measured using an ion specific 
electrode (NOVA-5+ electrolyte analyzer, Nova Biomedical, Waltham, MA). 24h sodium 
and water balances were calculated as 24h intake minus 24h excretion. Cumulative 
sodium and water balances were determined from sequential summation of daily balances 
over the duration of the protocol.  
 
Statistical Analysis 
Data were analyzed by 2-way analysis of variance for repeated measures followed by the 
Holm-Sidak method for all post-hoc comparisons (SigmaPlot version 10.0). A p value 
less than 0.05 was considered to be statistically significant. 
 
2.4 Results 
 
Cardiovascular Responses to Targeted Sympathetic Ablation 
As shown in Figure 2, MAP increased in all groups from ~120 mmHg on the final 
day of 0.1% NaCl diet (SHAM = 120.2 ± 2.2, RDNX =119.5 ± 2.0, CGX = 119.8 ± 1.3, 
RDNX-CGX = 118.3 ± 1.8 mmHg) to ~140 mmHg after three weeks of 4.0% NaCl 
(SHAM = 140.1 ± 3.1, RDNX = 140.9 ± 5.0, GCX = 139.4 ± 2.4, RDNX-CGX = 138.5 ± 
3.4 mmHg).  Following SHAM surgery, MAP fell transiently, most likely due to a 
transient decrease in food (and therefore sodium) intake (please see 
http://hyper.ahajournals.org Figures S1), but returned to the pre-surgery trajectory within 
7 days, reaching 165.0 ± 3.7 mmHg on the final day of the protocol. In contrast, MAP 
also fell in the RNDX group but did not rebound to the same trajectory and, by the end of 
the protocol, MAP was ~15 mmHg lower (150.4 ± 10.4) than SHAM rats.  The 
magnitude and time course of the MAP response to CGX was similar to that of RDNX 
rats with MAP reaching a final level of 147.0 ± 6.1 mmHg. Finally, RDNX-CGX resulted 
in a much greater decrease in MAP than RDNX or CGX alone with a final MAP of 128.4 
± 6.6, ~35 mmHg lower than SHAM rats and ~20 mmHg lower than RDNX and CGX 
rats on the final day of the protocol. Moreover, the maximum pressure response was 
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greater in RDNX-CGX than all other groups (please see http://hyper.ahajournals.org 
Figures S2). 
The effects of SHAM and targeted sympathetic ablation on HR are also shown in 
Figure 2. HR on the final day of baseline was similar in all groups (SHAM = 422.5 ± 2.7, 
RDNX =416.9 ± 4.9, CGX = 425.1 ± 4.1, RDNX-CGX = 420.6 ± 4.8 bpm) and 
decreased to a similar level after three weeks of high salt intake (SHAM = 380.0 ± 3.1, 
RDNX = 385.2 ± 3.0, CGX = 383.6 ± 2.8, 384.3 ± 2.9 bpm).  Following treatment 
surgery, HR transiently increased and then gradually fell in SHAM and RDNX rats such 
that HR was not statistically different between these groups throughout the protocol.  In 
contrast both CGX and RDNX-CGX rats exhibited a marked biphasic increase in HR 
following treatment. During the first peak, HR increased to 425.87 ± 10.5 in CGX rats 
and 450.22 ± 6.2 in RNDX-CGX rats and began to fall but then increased to a second 
peak before falling to levels slightly higher than SHAM and RDNX rats by the end of the 
protocol.  
 
Sodium and Water Balance Responses to Targeted Sympathetic Ablation 
Daily sodium and water intake, excretion and balance measurements were similar 
between all groups during the baseline period, increased transiently when the diet was 
increased to 4.0% NaCl, and returned to baseline levels until the time of SHAM or 
targeted sympathetic ablation (please see http://hyper.ahajournals.org Figures S1 and S3). 
There were no differences in these parameters between SHAM and RDNX rats at any 
time during the 4 weeks following surgery with the exception of the day after surgery 
when urine output was higher in RDNX than SHAM rats. Sodium and water intake, 
excretion and balance decreased transiently after SHAM and RDNX but returned to pre-
procedure levels within 10 days.  
Cumulative sodium and water balances over the duration of the protocol were 
calculated from the daily balance measurements in all 4 groups (Figure 3). There were no 
differences for cumulative sodium or water balance between RDNX and SHAM rats over 
the entire protocol. On the other hand, CGX rats retained sodium and water following 
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nerve ablation such that cumulative balances were significantly higher by the end of the 
protocol as compared to SHAM rats. This response was significantly attenuated by 
combining CGX with RDNX. 
 
Tissue Norepinephrine Content 
Tissues were collected at the end of the study to determine the extent of 
denervation 4 weeks post-procedure. Results of the norepinephrine assay clearly show 
that RDNX selectively denervated the kidneys, CGX selectively denervated the gut and 
RDNX-CGX denervated both (Figure 4). 
 
2.5 Discussion 
 
The sympathetic nervous system plays an important role in some forms of human 
hypertension; however, the degree to which sympathetic activity to the kidneys, relative 
to non-renal vascular beds, contributes to the pathogenesis and maintenance of essential 
hypertension remains unclear(57, 83, 115) .  The recent success of catheter based renal 
nerve ablation to treat drug resistant hypertension supports the concept that the kidneys 
are a key target of the sympathetic nervous system in hypertension, but it is still not clear 
whether other vascular beds are also important. 
The present study was designed to address this question by measuring the 
cardiovascular and fluid balance responses to targeted ablation of sympathetic nerves to 
the kidneys and the splanchnic vascular bed, separately and in combination, in Dahl S 
rats. The main findings of this study were: 1) RDNX decreased arterial pressure 
independent of changes in sodium and water balance; 2) CGX decreased arterial pressure 
to a similar magnitude as RDNX despite compensatory increases in HR and sodium and 
water balance; 3) combined RDNX and CGX induced the greatest fall in arterial pressure 
suggesting that the responses to RDNX and CGX are mediated by separate mechanisms. 
Overall, these results suggest that targeted sympathetic ablation is an effective treatment 
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for established hypertension in the Dahl S rat and that both the renal and splanchnic 
vascular beds are important sympathetic targets in this model.  
 
Renal denervation partially reverses salt-induced hypertension in Dahl S rats 
RDNX has no effect on the developmental phase of Dahl S hypertension (75, 132, 
176). However, the ability of RDNX to reverse this model of hypertension has not been 
reported. Compared to SHAM rats, arterial pressure was ~15 mmHg lower in RDNX rats 
throughout the 4 week post-procedure period. The mechanism(s) by which RDNX 
attenuate(s) any form of hypertension is a subject of great debate.  One explanation is that 
RDNX increases renal sodium and water excretion and causes a subsequent contraction 
of blood volume (36) by suppressing sympathetically mediated renin secretion and/or 
sodium reabsorption. However, we found no differences in daily or cumulative sodium 
and water balance between SHAM and RDNX rats.  This is consistent with our previous 
reports that RDNX decreases arterial pressure in normotensive Sprague Dawley rats 
independent of sodium balance or renin release (76, 78). It is important to note that 
RDNX did not affect the salt sensitivity of arterial pressure in Sprague Dawley rats (76) 
or Dahl S rats.  
Another possibility is that RDNX results in renal vasodilation. Although this 
hypothesis remains to be tested in the Dahl S rat, it was recently reported that renal nerve 
ablation in patients with drug resistant hypertension decreases renal vascular resistance 
with no change in glomerular filtration rate (112).  
A third possibility is that RDNX attenuates hypertension by ablation of centrally 
projecting afferent renal nerves reducing sympathetic activity to non-renal vascular beds. 
As Dahl S rats become increasingly hypertensive, renal injury worsens (151, 156, 157), 
and evidence suggests that kidney disease can drive afferent renal nerve-dependent 
sympathetically mediated hypertension (30, 63).  The progressive nature of this proposed 
kidney disease dependent sympathoexcitation may explain the difference in effectiveness 
of RDNX to reverse, rather than prevent Dahl S hypertension. However, it is important to 
34 
 
note that the arterial pressure response to RDNX may not require augmented afferent 
signaling since it occurs in normotensive Sprague-Dawley rats (76, 77).  
 
Celiac Ganglionectomy Partially Reverses Hypertension in the Dahl S Rat: Possible 
Role of Blood Volume Redistribution 
A novel finding of this study is that CGX decreased arterial pressure in Dahl S 
rats to a similar magnitude as RDNX.  To our knowledge this the first study, in any 
experimental model, demonstrating the ability of CGX to reverse hypertension. Although 
the mechanisms by which CGX reversed Dahl S hypertension were not explored, it is 
likely that, similar to our studies in the AngII-salt model (91), CGX decreased splanchnic 
vascular resistance and increased total vascular conductance, both of which would 
promote a redistribution of blood from the arterial to the highly compliant venous 
compartment. This hypothesis is in line with our recently published mathematical model 
of salt-sensitive hypertension in which the distribution of blood volume between a high 
compliant (i.e. splanchnic) and low compliant (i.e. kidney) vascular bed is determined by 
neural input to each vascular bed (9). Additional experiments will be needed to test this 
hypothesis. 
Sympathetic nerve activity was not measured in this study and therefore it 
remains to be tested whether the responses to CGX were due to decreased sympathetic 
nerve activity per se.  Alternative explanations include the possibility that ablation of 
sensory nerves in the gut may affect arterial pressure in non-sympathetically mediated 
ways (i.e. changes in immune system function or circulating levels of vasopressin). 
However, we have reported in other models that CGX decreases non-hepatic splanchnic 
norepinephrine spillover (85), and increases total vascular capacitance (91). These 
findings combined with measurements of tissue NE in the present study are most 
consistent with idea that CGX reduces sympathetic input to splanchnic vasculature 
resulting in decreased arterial pressure. This hypothesis remains to be tested by studies of 
the splanchnic hemodynamic responses to CGX in the Dahl S rat. 
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The magnitude and time course of the arterial pressure response to CGX was 
nearly identical to RDNX suggesting these procedures may act via a common pathway. 
However, the responses of the other variables suggest that RDNX and CGX reduced 
arterial pressure by separate mechanisms. Specifically, CGX resulted in marked 
tachycardia and sodium and water retention compared to SHAM and RDNX rats. These 
responses are consistent with activation of compensatory mechanisms to maintain arterial 
pressure following loss of sympathetic input to the splanchnic vascular bed which may 
reduce effective blood volume and therefore cardiac output (via increased venous 
capacitance and reduced atrial filling) and total peripheral resistance (46). These results 
are consistent with compensatory increases in both cardiac and renal sympathetic activity 
following CGX. The greater tachycardic response to RDNX-CGX compared to CGX 
suggests a baroreflex mediated increase in cardiac sympathetic activity since the 
antihypertensive effect of RDNX-CGX was  much greater than that of CGX. The blunted 
sodium and water retention following RDNX-CGX compared to CGX is consistent with 
the activation of renal sympathetic nerves following CGX. In addition, reduced atrial 
filling would be expected to inhibit the release of atrial natriuretic peptide (ANP) 
promoting sodium retention. The extent to which these mechanisms buffer the arterial 
pressure response to CGX in Dahl S rats remains to be determined. 
Another possibility is that the compensatory HR and fluid balance responses to 
CGX were secondary to volume depletion due to decreased sodium and water absorption 
from the small intestine, since some rats exhibited diarrhea following CGX  similar to 
previous studies using CGX (49, 118).  While we cannot discount this entirely, we do not 
feel it was a major contributor to the responses to CGX for several reasons. First, in past 
studies we have shown that CGX increases total vascular capacitance but has no effect on 
absolute blood volume (91). Second, although some rats exhibited transient diarrhea (1-2 
weeks), sodium retention persisted during the 2-3 weeks following the cessation of 
diarrhea. Finally, there was no correlation between final body weight (an index of 
nutrient absorption) and final arterial pressure in any group (please see 
http://hyper.ahajournals.org Figure S4). We conclude that the compensatory responses of 
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HR and fluid balance to CGX are secondary to a decrease in effective blood volume 
rather than a reduction in absolute volume. This hypothesis will be tested in future studies 
in which we measure the effect of CGX on mean circulatory filling pressure in Dahl S 
rats. 
 
Additive Effects of Renal and Splanchnic Denervation in the Treatment of 
Hypertension  
Further evidence that RDNX and CGX act via separate pathways is the fact that 
the combination of these treatments resulted in a greater response than either treatment 
alone.  In addition, based on analysis of tissue norepinephrine content, RDNX had no 
effect on the duodenum, liver or spleen and CGX had no effect on the kidneys. Taken 
together we conclude that the renal nerves and splanchnic nerves contribute to the 
maintenance of Dahl S hypertension independently of one another and therefore RDNX 
and CGX reduce arterial pressure via two distinct mechanisms. 
It is worth noting that the compensatory increases in HR and sodium and water 
retention seen in CGX rats were also observed in RDNX-CGX rats. The increase in HR 
during the first peak tended to be greater in RDNX-CGX rats than in CGX rats, which is 
consistent with a baroreflex mediated response as discussed above. Similarly, sodium 
retention in RDNX-CGX rats may have resulted from the greater fall in renal perfusion 
pressure, via the pressure-natriuresis relationship or suppression of plasma ANP as 
discussed above. 
 
2.6 Perspectives 
 
Renal nerve ablation has been shown to decrease arterial pressure in some human 
hypertensives; however, the lack of a method to quantitate the extent of denervation in 
humans makes it impossible to establish the efficacy of this treatment since failure to 
respond may be due to incomplete denervation or the fact that renal nerves do not 
contribute to all forms of human essential hypertension.  The Dahl S rat is an excellent 
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animal model for preclinical studies to address this issue.  The response of arterial 
pressure to renal denervation in this model suggests that this approach can partially 
reverse hypertension but sympathetic nerves to other target organs are also important. 
Specifically, our study suggests that targeted splanchnic nerve ablation may have an 
additional therapeutic effect and should be pursued as a possible stand-alone or adjunct 
treatment for hypertension in the future. Further studies are needed to establish the 
mechanisms underlying the antihypertensive effects of these interventions. 
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Novelty and significance 
What Is New? 
 RDNX and CGX both decrease arterial pressure in hypertensive Dahl S rats. 
 CGX and RDNX-CGX, but not RDNX cause increases in heart rate as well as 
sodium and water retention. 
 RDNX-CGX has an additive antihypertensive effect. 
 The responses to RDNX and CGX are mediated by different mechanisms. 
What Is Relevant? 
 RDNX decreased arterial pressure to a magnitude similar to that reported in 
humans. 
 CGX decreased arterial pressure as has been reported in human hypertensives. 
Summary 
The results of this study suggest that both the renal and splanchnic nerves contribute to 
the maintenance of Dahl S hypertension and that targeted ablation of the splanchnic 
sympathetic nerves should be considered as treatment option for hypertensive patients.   
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Figure 1.  Protocol timeline.  CGX = celiac ganglionectomy, RDNX = renal 
denervation, RDNX-CGX = combined celiac ganglionectomy and renal denervation, and 
SHAM = sham surgery. 
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Figure 2.  Effect of SHAM, RDNX, CGX and RDNX-CGX on MAP and HR.  * = p 
< 0.05 for RDNX-CGX vs. SHAM.  † = p < 0.05 for CGX vs. SHAM. ‡ = p < 0.05 for 
RDNX vs. SHAM. 
 
 
41 
 
 
 
 
Figure 3.  Effect of SHAM, RDNX, CGX and RDNX-CGX on cumulative sodium 
and water balance.  * = p < 0.05 for RDNX-CGX vs. SHAM.  † = p < 0.05 for CGX vs. 
SHAM. ‡ = p < 0.05 for CGX vs. RDNX-CGX. 
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Figure 4.  Effect of SHAM, RDNX, CGX and RDNX-CGX on norepinephrine (NE) 
content in the duodenum, liver, spleen, left kidney and right kidney. * = p < 0.05 vs. 
SHAM.  † = p < 0.05 vs. RDNX. ‡ = p < 0.05 vs. CGX. 
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Figure S1.  Effect of SHAM, RDNX, CGX and RDNX-CGX on sodium intake, 
excretion and balance. * = p < 0.05 for RDNX-CGX vs. SHAM.  † = p < 0.05 for CGX 
vs. SHAM. ‡ = p < 0.05 for RDNX vs. SHAM. 
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Figure S2.  Maximum arterial pressure response to SHAM, RDNX, CGX and 
RDNX-CGX (Max ΔMAP; the lowest MAP following surgery minus MAP on the day 
before surgery).   * = p < 0.05 vs. SHAM.  † = p < 0.05 vs. RDNX. ‡ = p < 0.05 vs. 
CGX. 
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Figure S3.  Effect of SHAM, RDNX, CGX and RDNX-CGX on water intake, urine 
output and water balance. * = p < 0.05 for RDNX-CGX vs. SHAM.  † = p < 0.05 for 
CGX vs. SHAM. ‡ = p < 0.05 for RDNX vs. SHAM. 
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Figure S4.  Final MAP vs. final body weight. No correlation exists between final MAP 
and final body weight in any group. 
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3.1 Summary 
 
Renal denervation has been shown to lower arterial pressure in some hypertensive 
patients, yet it remains unclear whether this is due to ablation of afferent or efferent renal 
nerves. To investigate the role of afferent renal nerves in arterial pressure regulation, 
previous studies have used methods that disrupt both renal and non-renal afferent 
signaling. The present study was conducted to develop and validate a technique for 
selective ablation of afferent renal nerves that does not disrupt other afferent pathways. 
To do this, we adapted a technique for sensory denervation of the adrenal gland by 
topical application of capsaicin and tested the hypothesis that exposure of the renal 
nerves to capsaicin (renal-CAP treatment) causes ablation of afferent but not efferent 
renal nerves. Renal-CAP treatment had no effect on renal content of the efferent nerve 
markers tyrosine hydroxylase and norepinephrine; however, the afferent nerve marker, 
calcitonin gene-related peptide was largely depleted from the kidney 10 days after 
treatment, but returned to roughly half of control levels by seven weeks post-treatment. 
Moreover, renal-CAP treatment abolished the cardiovascular responses to acute 
pharmacological stimulation of afferent renal nerves. Renal-CAP treated rats showed 
normal weight gain as well as cardiovascular and fluid balance regulation during dietary 
sodium loading. To some extent, renal-CAP treatment did blunt the bradycardic response, 
and increase the dipsogenic response to increased salt intake. Lastly, renal-CAP treatment 
significantly attenuated the development of deoxycorticosterone acetate-salt 
hypertension. These results demonstrate that renal-CAP treatment effectively causes 
selective ablation of afferent renal nerves in rats. 
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3.2 Introduction 
 
Numerous clinical trials have highlighted catheter based renal nerve ablation (renal 
denervation; RDNX) as a possibly viable antihypertensive treatment in patients with 
drug-resistant hypertension (43, 101, 114), although other studies have failed to show a 
significant antihypertensive effect of the treatment (13, 18). Despite the controversy 
surrounding these clinical data, RDNX has been consistently shown to reduce blood 
pressure in numerous animal models of hypertension (38) suggesting that when sufficient 
denervation is achieved, RDNX can have an antihypertensive effect in certain forms of 
hypertension. The failure of RDNX to reduce blood pressure in some cases highlights the 
importance of further understanding the mechanisms underlying the antihypertensive 
effect of RDNX. Specifically, since renal nerves contain both motor (efferent) and 
sensory (afferent) fibers, it is not known whether the antihypertensive response to RDNX 
is due to ablation of efferent nerves, afferent nerves, or both. Since elevated efferent renal 
nerve activity increases renal sodium reabsorption, renal vascular resistance and renin 
release, one hypothesis is that RDNX lowers arterial pressure secondary to a reduction in 
one or more of these parameters (36). Alternatively, elevated afferent renal nerve activity 
has been shown to increase sympathetic nerve activity to renal and non-renal vascular 
beds (135, 146) suggesting that RDNX may decrease arterial pressure by reducing 
sympathetic tone, not only to the kidney, but to other targets as well. Recent studies in 
humans with drug resistant hypertension support both of these hypotheses. Specifically, 
RDNX has been shown to decrease renal resistive index, likely resulting from a loss of 
efferent neural control of renal vascular tone (112). It has also been reported that RDNX 
decreases skeletal muscle sympathetic activity (67, 143), plasma glucose (113), incidence 
of cardiac arrhythmias (137, 158), and the frequency of episodes of sleep apnea (171).  
These responses likely result from ablation of afferent renal nerves. However, it should 
be noted that at least one study has shown no reduction in skeletal muscle sympathetic 
activity following RDNX (18).  
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Surgical RDNX has been used for decades in animal models to study the role of 
renal nerves in the regulation of renal and cardiovascular function (38). However, as is 
true with catheter based renal nerve ablation in humans, this method is non-selective 
since it disrupts both afferent and efferent neural pathways. To study the functions of 
afferent renal nerves specifically, a procedure termed dorsal rhizotomy has been used (97, 
98). This surgical technique interrupts afferent neural pathways from the kidney by 
sectioning the dorsal roots of the spinal cord at levels T9-L1. While this procedure 
removes a large portion of the renal afferent input into the spinal cord, it is not specific to 
renal afferents since it also disrupts all visceral, somatic and cutaneous afferent inputs at 
these spinal levels. This is particularly important since osmosensitive and sodium-
sensitive hepatoportal afferents, which are known to regulate efferent renal nerve activity, 
at least acutely (74, 121, 122), are also sectioned by this procedure. Moreover, we have 
previously shown that denervation of these afferents chronically increases arterial 
pressure in normal rats although we did not establish the role of renal nerves in this 
response (23). Another method used to disrupt afferent renal nerve signaling is systemic 
administration of the transient receptor potential (TRP) V1 receptor agonist, capsaicin, to 
neonatal rat pups (72, 164, 165, 168). It is well documented that capsaicin ablates small, 
unmyelinated C-fibers (47, 69) and this method destroys afferent neurons in the kidney; 
however, it is not specific for renal afferents since systemic delivery of capsaicin has 
been shown to cause degeneration of TRPV1+ sensory fibers throughout the body. 
Nonetheless, it is interesting to note that both dorsal rhizotomy and systemic capsaicin 
treatment have been reported to cause salt-sensitive hypertension in the rat (97, 164) and 
these findings have been interpreted as evidence that disruption of renal afferent signaling 
may be the cause of this salt-sensitive hypertension (97). However, since both methods 
are not selective for renal afferents, the possibility remains that the observed salt-
sensitive hypertension resulted from the ablation of other sensory afferents, such as 
hepato-portal osmoreceptors(122, 123). 
There is clearly a strong need for a technique to selectively ablate afferent renal 
nerves experimentally. Such a technique would be a valuable tool for studying the role of 
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renal afferent signaling in the regulation of renal and cardiovascular function, and could 
also pave the way for development of more refined renal nerve ablation therapies in 
humans.  The present study was conducted to address this need. The approach we used 
was adapted from our previous findings that topical application of capsaicin to the 
adrenal gland causes selective ablation of adrenal afferent nerves in the rat(159-161). 
Because the majority of renal afferent fibers are unmyelinated (or thinly myelinated) and 
capsaicin sensitive (93, 166), and TRPV1 receptors are localized along the axons of 
sensory fibers as well as nerve terminals (154), we hypothesized that periaxonal 
application of capsaicin to the renal nerves (renal-CAP treatment) would cause selective 
ablation of afferent renal nerves. 
We tested this hypothesis by quantifying the content of neuronal markers in the 
kidney at various time points following renal-CAP treatment using the afferent nerve 
marker, calcitonin gene related peptide (CGRP), and the efferent nerve markers tyrosine 
hydroxylase (TH) and norepinephrine (NE).  We also assessed the ability of renal-CAP 
treatment to abolish the afferent renal nerve-dependent cardiovascular responses to 
intrarenal infusions of bradykinin in conscious rats. Additionally, since previous studies 
using non-selective methods to ablate afferent renal nerves have suggested that impaired 
renal afferent signaling may be a determinant of salt-sensitive hypertension, we assessed 
the effect renal-CAP treatment on the regulation of arterial pressure and sodium/water 
balance in rats fed varying levels of dietary sodium. Finally, we tested whether the 
development of deoxycorticosterone acetate (DOCA)-salt hypertension, which has been 
proposed to be driven by afferent renal nerves (77), is attenuated by renal-CAP treatment. 
 
3.3 Materials and methods 
 
Animals and General Procedures 
With the exception of the experiments using intrarenal and intravenous bradykinin 
infusion, all experiments were performed at the University of Minnesota. For these 
studies, male Sprague Dawley rats were purchased from Charles River Laboratories 
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(Wilmington, MA) and housed in pairs in a temperature and light controlled room until 
the beginning of the study.  Rats were allowed access to standard rat chow and distilled 
water ad libitum during this pre-experimental period. For all surgical procedures 
performed in these experiments, rats were anesthetized with 2.0% isoflurane and atropine 
sulfate (0.2 mg/kg, intraperitoneal) and ketoprofen (5 mg/kg, subcutaneous) and 
gentamicin sulfate (2.5 mg/kg, intramuscular]) were administered prior to surgery.  For 
three days following surgery, ketoprofen (2.5 mg/kg, subcutaneous) was given once per 
day and the drinking water was supplemented with amoxicillin (1 mg/ml).  All 
procedures were approved by the University of Minnesota Animal Care and Use 
Committee and were conducted in accordance with the institutional and National 
Institutes of Health guidelines. 
The experiments to assess cardiovascular responses to intrarenal and intravenous 
infusions of bradykinin were conducted at Boston University. For these studies, male 
Sprague Dawley rats were purchased from Harlan Laboratories, Inc. (Indianapolis, IN) 
and housed individually in a temperature and light controlled room. Following 
completion of surgical procedures, rats received a standard rat chow and water ad 
libitum. All procedures were approved by the Boston University School of Medicine 
Institutional Animal Care and Use Committee and are in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. 
 
Surgical Procedures 
Renal-CAP Treatment: Rats were anesthetized, a midline abdominal incision was 
made and the visceral organs were externalized and reflected to expose the left kidney. A 
hole was made in the peritoneal membrane to expose the renal artery and vein. The fat 
surrounding the renal artery and vein was then gently dissected away from the vessels to 
expose the renal nerves. A small piece of gauze soaked in a capsaicin solution (33 mM in 
5% ethanol, 5% tween 80 and 90% normal saline) was wrapped around the renal artery 
and vein for 15 minutes. A small piece of parafilm was placed under the renal artery and 
vein prior to the placement of capsaicin-soaked gauze to prevent any non-renal capsaicin 
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exposure. Following 15 minutes of capsaicin exposure, the gauze and parafilm were 
removed, the area was dried, and the procedure repeated on the contralateral side if called 
for in the experimental protocol. At the end of the procedure, the viscera were replaced 
and the abdominal muscles and skin were closed separately with 3-0 silk suture. The 
sham control treatment was performed by externalizing the viscera, visualizing the renal 
artery and vein, replacing the organs and then closing the wound as described above. 
Complete Renal Denervation (RDNX): Denervation of both afferent and efferent 
renal nerves was performed as previously described (77). Briefly, rats were anesthetized 
with 2% isoflurane and the left renal nerves were then exposed through a midline 
abdominal incision. Using a dissecting microscope, the renal vein and artery were 
dissected out of the surrounding fascia and stripped of all visible renal nerve bundles. 
Following dissection, the renal artery was painted with 10% phenol in ethanol to ensure 
the destruction of any remaining renal nerve fibers. This procedure was then repeated on 
the contralateral side and the incisions closed. 
Instrumentation for Acute Assessment of Afferent Renal Nerve Functionality: On 
the day of acute bradykinin experiments, rats were anesthetized with sodium 
methohexital (20mg/kg, intraperitoneal; supplemented with 10 mg/kg, intravenous as 
required). To allow for intrarenal infusion of bradykinin, the left kidney was exposed 
through a small flank incision. A catheter (polyethylene; PE 10) was then placed in a 
branch of the left renal artery and exteriorized through the flank incision and the incision 
was closed. Collection of urine was achieved through a catheter (polyethylene; PE 240) 
inserted into the urinary bladder via a midline abdominal incision. The catheter was 
exteriorized through this incision and the incision was closed. An additional incision was 
made in the left inguinal area. The left femoral vein was catheterized (polyethylene; PE 
50) for intravenous infusion of saline or drugs and the left femoral artery was catheterized 
(polyethylene; PE 50) for measurement of mean arterial pressure (MAP) and heart rate 
(HR). Both catheters were exteriorized at the incision site and the incision was closed.  
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Validation of renal-CAP treatment by IHC 
To test the efficacy of renal-CAP treatment to cause selective ablation of afferent 
renal nerves, and to determine whether reinnervation occurs over time, male Sprague 
Dawley rats (58-65 days old, 220-330g) were subjected to either bilateral renal-CAP or 
SHAM treatment and sacrificed after 10 days or 4 weeks. Kidneys were then collected 
for immunohistochemical labeling of the efferent nerve-specific marker TH and the 
afferent nerve-specific marker CGRP. Additionally, IHC data for a 7-week post-treatment 
time point were obtained from rats that underwent the salt-sensitivity protocol described 
below. 
At the endpoint, rats were anesthetized with 2% isoflurane, euthanized by 
exsanguination and kidneys were immediately removed, rinsed in normal saline and 
placed in 10% neutral buffered formalin until the time of sectioning. Kidneys were 
embedded in paraffin and cut longitudinally at a thickness of 5 µm. Sections were 
deparaffinized and subjected to heat induced epitope retrieval (HIER) in a Decloaking 
Chamber (Biocare Medical; Model DC2008US) using Antigen Decloaker solution 
(Biocare Medical; CB910M) at 95°C. Sections were incubated in Protein Block Serum-
Free (Dako; X0909) then in a polyclonal CGRP antibody (Enzo; BML-CA1134-0100) 
diluted to 1:500 in DaVinci Green Universal Diluent (Biocare Medical; PD900). 
Endogenous peroxidases were blocked with Peroxidazed 1 (Biocare Medical; PX968M) 
and sections were incubated in an anti-rabbit:HRP polymer (Invitrogen; 87-9263). 
Betazoid DAB Chromogen (Biocare Medical; BDB2004MM) was then applied to each 
slide and sections were incubated with Protein Block Serum-Free. Sections were then 
incubated in a rabbit polyclonal TH antibody (Abcam; ab112) diluted to 1:1000 followed 
by Mach 3 Probe (Biocare Medical) and Mach 3 Rabbit AP-Polymer (Biocare Medical; 
M3R533L). Sections were then incubated in Warp Red Chromogen (Biocare Medical; 
WR806S) and counterstained with Mayer’s Hematoxylin (Electron Microscopy Sciences; 
26043-06). Each slide was dipped in xylene and a coverslip was applied with Surgipath 
Micromount permanent mounting media (Leica; 3801731). 
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To quantify the labeling of CGRP and TH, IHC slides were digitally 
photographed and the images were analyzed using the Positive Pixel Count v9 algorithm 
in ImageScope software v11 (Aperio Technologies, Vista, CA). Because CGRP labeling 
was confined to the renal pelvis, CGRP content was quantified as the area of CGRP+ 
labeling (µm2) per length of pelvic wall analyzed (mm). Because TH labeling was most 
robust in the large nerve bundles found in the hilum of the kidney, TH was quantified as 
the percent area of a major nerve bundle that was labeled positive for TH. Quantification 
was done by individuals blinded to the experimental group.  
 
Validation of renal-CAP treatment by ELISA and HPLC  
We also used an enzyme-linked immunosorbent assay (ELISA) for CGRP and 
high-performance liquid chromatography (HPLC) for NE to quantify the extent of 
selective afferent renal nerve ablation and the time course of reinnervation. Male Sprague 
Dawley rats (59-74 days old, 230-375g) were subjected to unilateral renal-CAP treatment 
of the left kidney, with the right kidney serving as a sham-operated control. Rats were 
sacrificed 10 days, 4 weeks or 7 weeks after treatment and kidneys were collected and 
assayed for content of CGRP and NE.  
Kidneys were removed immediately after death; the renal artery, renal vein, ureter 
and capsule were removed; and the kidneys were placed in a cold normal saline bath for 
further dissection. Renal parenchymal samples were taken from the poles and lateral 
portion of the kidney and flash frozen in liquid nitrogen. The renal pelvis was then 
carefully dissected from the remaining portion of kidney and flash frozen in liquid 
nitrogen. All frozen samples were stored at -80°C until being assayed. 
The parenchymal samples were assayed for NE using HPLC as previously 
described (107). The isolated renal pelvic samples were assayed for CGRP content using 
a commercially available ELISA kit (Cayman Chemicals; Ann Arbor, MI; Item Number 
589001). Tissues were homogenized in 1M acetic acid and CGRP was extracted using 
C18 Sep-columns (Peninsula Laboratories; San Carlos, CA; Item Number Y-1000). To 
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eliminate any interassay variance, all pelvic samples were run on single 96 well ELISA 
plate. 
 
Functional validation of renal-CAP treatment 
A test of afferent renal nerve functionality was conducted in male Sprague 
Dawley rats (275-300 g) 7-10 days after being subjected to either SHAM or bilateral 
renal-CAP treatment (n = 6 per treatment group). On the day of the acute experiment, rats 
were instrumented as described above. Rats were then placed in a plexiglass holder and 
an intravenous infusion of sterile isotonic saline (20µl/min) was maintained for a 2 hour 
surgical recovery period prior to experimentation to enable the animal to regain full 
consciousness and cardiovascular and renal excretory function to stabilize.  
MAP and HR were continuously recorded via the surgically implanted femoral 
artery cannula using computer-driven BIOPAC data acquisition software (MP150 and 
AcqKnowledge 3.8.2, CA) connected to an external pressure transducer (P23XL; Viggo 
Spectramed Inc., CA). MAP and HR were measured during a 20 minute control period. 
Bradykinin was then infused, in a random order, at concentrations of 5, 10, 20 and 40 
μg/kg/min either intravenously or intrarenally for a period of 5 min per dose per 
administration route. MAP and HR were recorded as the average value of the last 2 
minutes of each infusion period. 
    
Effect of renal-CAP treatment on cardiovascular and fluid balance responses to 
increased salt intake  
In order to determine whether renal-CAP treatment adversely affects 
cardiovascular and fluid homeostasis under conditions of chronic sodium loading, rats 
were subjected to the following protocol. Male Sprague Dawley rats (71-72 days old, 
330-390 g) underwent bilateral renal-CAP (n = 8) or SHAM treatment (n = 8) and were 
implanted with radiotelemeters (model TA11PA-C40, Data Sciences, Int., St. Paul, MN) 
to measure MAP and HR as previously described (162).  The rats were fed a 0.1% NaCl 
diet (Research Diets, New Brunswick, NJ) and allowed to recover for 10 days. After a 4 
57 
 
day baseline period, the diet was increased to 4% NaCl (Research Diets) for 3 weeks then 
8% NaCl (Research Diets) for 2 weeks. The animals were housed in metabolic cages 
(Techniplast 3701M001, Buguggiate, Italy) for daily measurement of sodium intake, 
sodium excretion, water intake and urine output.  At the end of the protocol, rats were 
sacrificed and kidneys were collected for immunohistochemical analysis of TH and 
CGRP.  
The radiotelemeter signal was monitored by a receiver (model RPC-1, Data 
Sciences, Int.) mounted on the side of the metabolic cage and connected to a Data 
Exchange Matrix (Data Sciences, Int.). The arterial pressure signal was sampled at 500 
samples/second for 10 seconds every 4 minutes using Dataquest A.R.T.™ Platinum 
Acquisition software (version 4.30, Data Sciences, Int.). HR was determined from the 
arterial pressure profile using the same software. 24-hour (24h) averages of MAP and HR 
were determined and plotted for each day of the study. 
24h food intake, water intake and urine output were measured gravimetrically. 
24h sodium intake was calculated by multiplying food intake (grams) and sodium content 
of the diet (0.1% NaCl = 0.01711 mmol Na+/g food; 4.0% NaCl = 0.6844 mmol Na+/g 
food; 8.0% NaCl = 1.3688 mmol Na+/g food). 24h sodium excretion was calculated by 
multiplying 24h urine output (ml) and urinary sodium concentration (mmol Na+/ml), 
which was measured using an ion specific electrode (NOVA-5+ electrolyte analyzer, 
Nova Biomedical, Waltham, MA). 24h sodium and water balances were calculated as 
24h intake minus 24h excretion.  
 
Effect of renal-CAP treatment on the development of DOCA-salt hypertension 
We have previously reported that RDNX attenuates the development of 
hypertension in the DOCA-salt model by 50% and hypothesized this was due to ablation 
of renal afferent nerves (77).  Therefore, to test whether the antihypertensive effect of 
RDNX in the DOCA-salt model is due to ablation of afferent renal nerves, rats underwent 
either SHAM, RDNX or renal-CAP treatment and were subjected to DOCA-salt 
treatment as previously described (77). Briefly, male Sprague-Dawley rats (285-400g) 
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underwent left unilateral nephrectomy and were allowed two weeks for compensatory 
renal hypertrophy. Rats were then subjected to SHAM, RDNX or renal-CAP and 
implanted with a radiotelemeter (Data Sciences, Int.) for measurement of MAP and HR. 
After ten days of recovery and three days of baseline, silicone pellets containing a total of 
100 mg DOCA were implanted subcutaneously between the scapulae. 3 weeks after 
DOCA implant, rats were sacrificed and kidneys were harvested for tissue assays of 
CGRP and NE content as described earlier. 
DOCA implants were made by mixing 100 mg DOCA into 2 ml of silicone 
(Sylgard 184 silicone elastomer base; Dow Corning, Midland, MI). Once the DOCA was 
homogenously mixed into the silicone, silicone elastomer curing agent (0.2 ml) was 
added. The DOCA implants were allowed to cure at room temperature for 24 hours and 
were then stored at 4°C until implantation. Each DOCA implant was cut into 2 to 3 mm 
cubes that were then implanted subcutaneously between the scapulae. 
 
Statistical Analysis 
The magnitude of the changes in cardiovascular and renal excretory parameters 
following intrarenal or intravenous infusion of bradykinin as well as differences in daily 
measurements generated from the salt-sensitivity and DOCA-salt protocols were 
analyzed by 2-way analysis of variance for repeated measures followed by the Bonferroni 
method for post-hoc comparisons (SigmaPlot version 12.3, Systat Software Inc., San 
Jose, CA). All body weight, IHC, ELISA, HPLC and baseline MAP and HR data were 
analyzed by one-way analysis of variance followed by the Bonferroni method for post-
hoc comparisons (SigmaPlot version 12.3). For the time course of reinnervation, a linear 
regression (SigmaPlot version 12.3) was performed. For all statistical analyses, a p value 
less than 0.05 was considered to be statistically significant. 
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3.4 Results 
 
Validation of renal-CAP treatment by immunohistochemistry  
Figure 1 shows representative immunohistochemistry images of a SHAM (top) 
and a renal-CAP (bottom) treated kidney 10 days post-treatment. Robust labeling of TH 
is apparent in both kidneys while the significant amount of CGRP labeling seen in the 
SHAM kidney is absent in the renal-CAP kidney. Because careful examination of all 
sections revealed that CGRP labeling was observed in the renal pelvis exclusively, CGRP 
was quantified as area of CGRP+ labeling per length of pelvic wall. TH labeling was 
found throughout the kidney but was most robust in the large nerve bundles near the 
hilum of the kidney, so TH was quantified as percent area of a nerve bundle with TH+ 
labeling. Labeling of CGRP and TH was quantified in SHAM and renal-CAP kidneys 10 
days, 4 weeks and 7 weeks post treatment (Figure 2A and 2B). TH labeling was not 
different between SHAM and renal-CAP kidneys at any time point. In contrast, CGRP 
labeling was nearly abolished 10 days and 4 weeks post renal-CAP treatment. By 7 
weeks post-treatment, CGRP labeling returned to approximately 50% of that observed in 
SHAM treated kidneys. 
 
Validation of renal-CAP treatment by ELISA and HPLC  
While IHC is useful for visualizing neurons of interest, more accurate 
quantification of neuromarkers can be obtained by assaying tissues for content of 
neurotransmitters. Therefore, we measured pelvic CGRP content by ELISA and renal NE 
content by HPLC at 10 days, 4 weeks and 7 weeks after unilateral renal-CAP treatment, 
using the non-treated kidney as a SHAM control. As shown in Figure 2C, renal NE 
content was not different between SHAM and renal-CAP kidneys at any time point. 
Conversely, renal pelvic CGRP was undetectable 10 days after renal-CAP treatment. 
Pelvic CGRP began to return to detectable levels at 4 weeks and, by 7 weeks, had 
returned to roughly 50% of control levels (Figure 2D). Figure 3 shows CGRP content 
over time in renal-CAP treated kidneys plotted as % of control (the ratio of CGRP 
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content of the left renal pelvis to right renal pelvis X 100) and suggests that the time 
course of afferent reinnervation is roughly linear, i.e., once initiated, afferent 
reinnervation occurs at a fairly constant rate.  
 
Effect of renal-CAP treatment on cardiovascular responses to activation of afferent 
renal nerves in conscious rats 
Infusion of bradykinin into the renal artery has been shown to activate afferent 
renal nerves (4, 172) and increase MAP and HR (146). Therefore, to determine whether 
renal-CAP treatment causes functional ablation of afferent renal nerves, experiments 
were conducted in conscious rats in which the physiological responses to direct 
pharmacological activation of afferent renal nerves by bradykinin were assessed. There 
were no significant differences between groups in baseline MAP (SHAM = 124 ± 3 
mmHg, renal-CAP = 121 ± 2 mmHg) or HR (SHAM = 414 ± 18 BPM, renal-CAP = 427 
± 16 BPM). More importantly, as shown in Figure 4, bradykinin infused into the renal 
artery evoked a dose dependent increase in MAP and HR in SHAM, but not renal-CAP 
rats. The same doses of bradykinin administered intravenously had no effect on MAP or 
HR in either SHAM or renal-CAP rats.  Sodium excretion was unaffected by bradykinin 
infusion given by either route (data not shown).  
 
Effect of renal-CAP treatment on cardiovascular and fluid balance regulation 
during chronic salt loading 
An additional experiment was conducted to determine if renal-CAP treatment 
disrupts cardiovascular and fluid balance regulation during chronic increases in dietary 
salt intake. Such dysregulation could occur as a result of non-specific effects of renal-
CAP treatment (i.e., ablation of efferent renal nerves) or secondary to disruption of 
normal dietary sodium-induced renal afferent signaling.  Figure 5 shows MAP and HR in 
SHAM and renal-CAP treated rats fed increasing levels of dietary salt. Renal-CAP 
treatment had no effect on the basal level of MAP when rats were being fed a low (0.1%) 
salt diet. Similarly, the response of MAP to a 40-fold (4.0% NaCl) and 80-fold (8.0% 
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NaCl) increase in salt intake was not different between renal-CAP and SHAM treated 
rats. Conversely, the progressive bradycardia observed in SHAM rats in response to 
increasing dietary sodium was significantly attenuated in renal-CAP rats.  
Figure 6 shows sodium intake, excretion and balance throughout the protocol. 
There were no differences in sodium intake between SHAM and renal-CAP treated rats at 
any level of dietary salt; 0.1%, (~ 0.4 mmol/day), 4.0% (~ 17 mmol/day) and 8.0% (~ 31 
mmol/day). Furthermore, the renal sodium excretory responses to these large increases in 
salt intake were not different between renal-CAP and SHAM treated rats throughout the 
protocol. As a result, there were no differences in sodium balance between groups over 
the 40-day protocol. Likewise, water intake and urine output were largely similar 
between groups throughout the protocol with the exception that renal-CAP rats tended to 
drink more water and excrete more urine than SHAM rats initially when diets were 
changed from 0.1% to 4.0% and from 4.0% to 8.0% (Figure 7). Water balance was 
similar between groups on all days of the protocol. 
Table 1 shows body weight at the time of treatment (bilateral renal-CAP or 
SHAM) and sacrifice 10 days, 4 weeks or 7 weeks post-treatment as well as the total 
weight gain from time of treatment to the time of sacrifice. Consistent with our findings 
that renal-CAP treatment does not adversely affect food intake or maintenance of body 
fluid balance during chronic dietary salt loading, these data demonstrate that renal-CAP 
treatment does not affect the rate of body weight gain over the same period of time.  
 
Effect of renal-CAP treatment on the development of DOCA-salt hypertension 
An additional experiment was conducted to test whether renal-CAP treatment 
attenuates a model of hypertension that is thought to be mediated by afferent renal 
nerves, the DOCA-salt model. As shown in Figure 8A, baseline MAP trended lower in 
RDNX rats as compared to SHAM and renal-CAP rats, and baseline HR was not 
different between groups. After 3 weeks of DOCA treatment, MAP in the SHAM group 
had increased ~ 30 mmHg above baseline (Figure 8B). In confirmation with data we have 
previously reported (77), this increase was attenuated by ~50% in RDNX rats. 
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Importantly, renal-CAP treatment had a nearly identical antihypertensive effect to 
RDNX. Neither RDNX nor renal-CAP had an effect on the change in HR observed with 
DOCA implantation (Figure 8B). As shown in Figure 9, both RDNX and renal-CAP 
treatment caused significant reductions in the renal pelvic content of the afferent nerve 
marker, CGRP, whereas RDNX and not renal-CAP treatment drastically reduced renal 
content of the efferent nerve marker, NE in DOCA-salt rats. 
 
3.5 Discussion 
 
The role of renal nerves in arterial pressure regulation and hypertension has been 
investigated in various animal models for years (38, 48, 77). Furthermore, recent 
technological advances have raised interest in targeting the renal nerves for the treatment 
of human hypertension (43, 101, 114) as well as other diseases such as diabetes (113) and 
sleep apnea (171). However, the promising clinical trials using RDNX have sparked 
many questions that need to be answered in order to optimize the effectiveness of renal 
nerve ablation. Chief among these is whether the antihypertensive effect of RDNX is due 
to ablation of afferent or efferent renal nerves. Clarification of this point is critical to our 
understanding of the pathophysiological mechanisms involved and to the development of 
more targeted nerve ablation approaches.  
In the present study we investigated the ability of periaxonal application of the 
TRPV1 receptor agonist, capsaicin, on renal nerves to selectively ablate afferent renal 
nerves while leaving efferent nerves intact. While capsaicin is known to activate sensory 
neurons acutely, it is also neurotoxic following prolonged exposure (69, 154). Systemic 
administration of capsaicin to neonatal rat pups results in whole body sensory nerve 
denervation (79), and local periaxonal application of capsaicin has been shown to 
selectively ablate sensory fibers of specific organs, such as the adrenal gland(159-161). 
Moreover, since the TRPV1 receptor is expressed along the axons of sensory fibers, but 
is not expressed in sympathetic efferent neurons (154), we hypothesized that periaxonal 
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application of capsaicin could be used to selectively ablate sensory fibers in the kidney 
while leaving efferent fibers intact. 
 
Renal-CAP treatment causes temporary selective loss of afferent nerve markers 
from the kidney as assessed by IHC and tissue assays 
Confirmation of sympathetic denervations has typically been achieved by 
assessing the content of NE in the denervated tissue and measurement of renal NE 
content by HPLC is the most commonly used and widely accepted method to confirm 
RDNX as successful in animals. We have performed numerous studies investigating the 
effect of RDNX on the pathogenesis of experimental hypertension and, using HPLC, 
typically report renal NE content to be reduced by 90-95% in renal denervated rats 
compared to control animals (48, 76-78, 91). While useful, it is important to note that this 
method does not assess ablation of afferent renal nerves, which is typically done by 
measurement of the neurotransmitters CGRP, or substance P (SP). 
In the present study, we quantified the content of neurochemical markers of 
efferent (TH and NE) and afferent (CGRP) nerves in SHAM or renal-CAP treated 
kidneys. We found that renal-CAP treatment virtually eliminated renal pelvic CGRP 
content without affecting renal NE or TH content.  Pelvic CGRP was undetectable 10 
days post-treatment by ELISA, but did recover over time. This recovery occurred linearly 
over time with levels ~20% and ~50% of control at 4 and 7 weeks post-treatment 
respectively.  
The time course of afferent reinnervation following renal-CAP treatment 
observed in the present study is strikingly similar to a recent investigation of the 
reinnervation pattern following complete surgical RDNX in rats (125). In this study, 
Mulder and coworkers used IHC to label markers of efferent nerves (TH and 
neuropeptide Y; NPY) and afferent nerves (CGRP and SP) in renal denervated and sham 
operated kidneys at various time points after treatment.  Labeling for the efferent makers 
TH and NPY in the renal cortex was nearly eliminated 4-5 days after RDNX, but returned 
to ~50% by 4 weeks. A very similar pattern was observed for the afferent markers CGRP 
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and SP in the pelvic wall. In the present study, IHC revealed that renal-CAP treatment 
reduced pelvic CGRP labeling to ~10 and 20% of control at 10 days and 4 weeks post 
treatment, respectively. In addition, using an ELISA for CGRP, we found that renal-CAP 
reduced renal pelvic content to undetectable levels at 10 days post-treatment and 20% of 
control at 4 weeks. In our study both methods (IHC and ELISA) demonstrated that pelvic 
CGRP returns to ~50% of control levels by 7 weeks post treatment. Although this time 
point was not measured in the study by Mulder and colleagues, they did report that NPY, 
TH, CGRP and SP returned to 100% of control by 12 weeks post treatment. In the present 
study, linear regression analysis of pelvic CGRP versus time post treatment suggests that 
pelvic GGRP would return to 100% of control 14 weeks post treatment. Based on the 
result of two independent measurements of the presence of afferent renal nerves, IHC for 
CGRP and ELISA for CGRP content, we conclude that renal-CAP treatment results in 
ablation of afferent renal nerves as effectively as, if not more effectively than, surgical 
RDNX. Moreover, in contrast to surgical RDNX, this technique does not cause ablation 
of efferent renal nerves as assessed by renal NE and TH content. 
 
Renal-CAP treatment causes functional ablation of afferent renal nerves 
Because depletion of neural markers does not necessarily correspond with a loss 
of neuronal function, we performed experiments in conscious rats to determine whether 
renal-CAP treatment causes functional ablation of afferent renal nerves. In these 
experiments, we measured the cardiovascular responses to intrarenal infusions of 
bradykinin, which has been shown to stimulate afferent renal nerves (4, 172) and increase 
MAP and HR (68, 146). To control for non-renal effects of bradykinin, intravenous 
infusions were given at the same doses.  
Bradykinin infused into the renal artery of SHAM rats caused a dose dependent 
increase in MAP and HR and these responses were absent in renal-CAP rats. Since 
intravenous infusions at the same doses caused no changes in MAP or HR, we conclude 
that the responses to intrarenal infusion were indeed due to intrarenal actions of 
bradykinin. More importantly, abolition of these responses by renal-CAP treatment 
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confirms previous reports that these responses are mediated by activation of afferent renal 
nerves and that renal-CAP results in complete functional ablation of afferent renal nerves. 
These results suggest that, in addition to causing loss of the neurotransmitter CGRP, 
renal-CAP treatment results in a complete loss of afferent neuronal function.  
 
Renal-CAP treatment does not affect the regulation of arterial pressure, fluid 
balance or weight gain during chronic dietary salt loading 
In addition to examining the effectiveness of renal-CAP treatment in selectively 
ablating afferent renal nerves, we sought to determine whether renal-CAP treatment 
causes a disruption in the regulation of fluid balance and arterial pressure during chronic 
increases in dietary salt intake. This could potentially occur as a result of non-specific 
effects of renal-CAP treatment (i.e. ablation of renal efferent nerves) or secondary to 
disruption of normal renal afferent signaling as suggested by earlier studies using non-
selective methods of afferent renal denervation such as dorsal rhizotomy (97) and 
systemic administration of capsaicin (164, 165, 168).  In the present study, renal-CAP 
treatment did not affect the regulation of arterial pressure or sodium and water balance in 
response to increasing dietary salt intake 40 and 80-fold from baseline over a period of 5 
weeks. Additionally, renal-CAP treated rats gained weight to a similar extent as SHAM 
rats. We conclude that, while renal-CAP is an effective treatment for targeted ablation of 
CCRP+ afferent renal nerves, this treatment does not interfere with regulation of arterial 
pressure, fluid balance or body weight gain in normotensive Sprague Dawley rats 
subjected to dietary sodium loading. 
Previous studies have shown that non-selective renal “deafferentation” causes 
salt-sensitive hypertension (97, 164, 165, 168). This was not observed in the present 
study using a more selective method for ablation of afferent renal nerves. In addition, we 
have previously reported that complete surgical RDNX (ablation of both afferents and 
efferents) also has no effect on the salt-sensitivity of arterial pressure or regulation of 
sodium and water balance in normotensive Sprague Dawley rats (76, 78). There are at 
least two explanations for the discrepancy between the results of the present study and 
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those of previous studies. The first is that the non-specific methods used previously also 
target non-renal visceral afferent pathways that are salt-sensitive such as hepatoportal 
osmoreceptors(122, 123). These sodium sensors have been shown to be important in the 
inhibition renal sympathetic nerve activity following hypertonic saline infusion into the 
portal vein and cause suppression of efferent renal nerve activity following ingestion of 
meals high in sodium content (74, 121, 129). Therefore it is possible that any method that 
disrupts afferent signaling from these receptors may result in sodium retention and 
hypertension.  The second possible explanation for the differences between studies is the 
method of arterial pressure measurement. In the current study, arterial pressure was 
measured continuously by radio telemetry in unrestrained rats. In contrast, previous 
studies employed methods that are known to induce acute stress responses such as 
indirect tail cuff measurements in restrained rats (164, 165, 168), acute direct recordings 
in anesthetized rats (164, 165), or acute direct recordings in conscious rats days after 
catheter implantation (97). Thus, it is possible that in the earlier studies, afferent renal 
nerve ablation led to exaggerated arterial pressure responses to acute stress in rats 
consuming a high salt diet. Both of these possibilities remain to be investigated. It is 
important to note that, whereas renal-CAP treatment had no effect on the basal level of 
arterial pressure in rats consuming a normal salt diet, we have consistently found that 
complete surgical RDNX decreases arterial pressure ~10 mmHg (76, 78). This suggests 
that the chronic hypotensive response to complete RDNX in non-hypertensive Sprague 
Dawley rats is due to loss of efferent renal nerves exclusively. 
 
Renal-CAP treatment amplifies the dipsogenic response and attenuates the 
bradycardic response to increased dietary sodium intake 
Another interesting finding in this study was that renal-CAP treated rats drank 
more water than control rats during the initial increases in salt intake. This occurred when 
dietary salt was increased from 0.1% to 4.0% NaCl and from 4.0% to 8.0% NaCl. 
Although we did not measure plasma vasopressin (AVP) in this study, it has been 
suggested that afferent renal nerves influence AVP release (25, 28, 35, 144). One 
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explanation for our findings is that renal-CAP rats had an impaired AVP response to 
acute increases in plasma osmolality and compensated by increasing water intake. 
Additionally, it is possible that afferent renal nerves play a direct regulatory role in the 
dipsogenic response to increases in dietary sodium load. While this is an interesting 
finding, the mechanism underlying this observation remains to be investigated.  
Finally, while we saw no differences in MAP between sham and renal-CAP rats, 
we did observe an effect of renal-CAP on chronic regulation of HR during increased 
dietary salt intake. Specifically, the bradycardic response to dietary sodium loading that 
was observed in SHAM rats was significantly attenuated by renal-CAP treatment. This 
suggests a role of afferent renal nerve signaling in the regulation of HR under conditions 
of high salt intake. This hypothesis remains to be tested by further studies. 
 
Afferent renal nerves mediate the development of DOCA-salt Hypertension 
Having shown that afferent renal nerves play a minimal role in the regulation of 
arterial pressure in normotensive rats, we performed one additional experiment to explore 
the role of these nerves in hypertension. We have previously reported that RDNX 
attenuates the development of DOCA-salt hypertension by 50% and hypothesized this 
was mediated by, at least in part, ablation of afferent renal nerves (77).  This hypothesis 
was based on the difference in magnitudes of the bradycardic response to DOCA-salt 
treatment in SHAM and RDNX rats. Although HR decreased in both groups, it was 
significantly higher in SHAM rats despite the fact that arterial pressure was also higher in 
these rats. We hypothesized that afferent renal nerves modulate baroreflex control of HR 
in DOCA-salt rats and that RDNX blocks this modulation secondary to ablation of renal 
afferent nerves (77). Moreover, we hypothesized that the antihypertensive effect of 
RDNX was due to ablation of afferent renal nerves. 
To test this hypothesis, we subjected DOCA-salt rats to SHAM, RDNX or renal-
CAP treatment. The results of present experiment show clearly that selective ablation of 
afferent renal nerves by renal-CAP treatment attenuates the development of DOCA-salt 
hypertension over the same time course and by the same magnitude as RDNX, suggesting 
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that the antihypertensive effect of RDNX in the DOCA-salt model is due to ablation of 
afferent rather than efferent renal nerves.  
Neither renal-CAP treatment nor RDNX had a significant effect on the HR 
response to DOCA implantation over the 21 day protocol which is consistent with our 
previous report in which we observed no significant difference in HR between SHAM 
and RDNX rats until after 4 weeks of DOCA (77). This observation is also consistent 
with the salt-sensitivity study in which renal-CAP treatment had no effect on HR 
compared to SHAM until after 3 weeks of high salt. While the results of our previous 
DOCA-salt study and the current salt-sensitivity study suggest a role of afferent renal 
nerves in HR regulation, this role seems to be minor and only apparent during long-term 
protocols. Further studies will be needed to fully elucidate the role of afferent renal 
nerves in HR regulation. 
The results of this study are important because they raise the possibility that the 
antihypertensive effect of RDNX in some humans may be due to ablation of afferent 
rather than efferent renal nerves. Further studies will be needed in order to determine the 
mechanisms underlying this antihypertensive effect, but some possibilities include 
decreased sympathetic outflow to renal and/or non-renal targets or decreased plasma 
AVP levels. Understanding the mechanisms underlying this antihypertensive effect may 
be critical to our understanding of the therapeutic effects of RDNX and to the 
development of more refined treatments. 
 
3.6 Limitations 
 
The primary limitation to the present study is that renal-CAP treatment is effective in 
temporarily ablating CGRP containing afferent renal neurons, it is not clear to what 
extent this procedure is effective in total “deafferentation” of the kidney as it does not 
target sensory neurons in the kidney that lack the TRPV1 receptor. Although the 
conventional view is that the vast majority of renal afferents are indeed TRPV1+, this is 
open to further investigation. Additionally, it is possible that the antihypertensive effect 
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of renal-CAP treatment is due to a non-specific action of capsaicin; however, this is 
unlikely since the capsaicin solution is well contained to the treatment area during the 
application period and the effects of RDNX and renal-CAP on arterial pressure were 
identical. 
 
3.7 Perspectives and Significance 
 
While RDNX has been shown to lower arterial pressure in some humans with resistant 
hypertension, it is not known whether the antihypertensive effect is due to ablation of 
afferent or efferent renal nerves. To this point, it is possible that there are some patients 
for whom RDNX will work by disrupting renal efferent signaling and some for whom it 
will work by reducing renal afferent signaling. Therefore, it is crucially important to 
address 1) whether afferent renal nerves are involved in hypertension, 2) if they are 
involved, whether we can target afferent renal nerves specifically in order to optimize the 
efficacy and reduce the possible side effects of RDNX and 3) whether we can identify 
patients who would benefit from afferent- or efferent-specific renal nerve ablation. As a 
first step toward addressing these points, we have developed a method for selective 
ablation of afferent renal nerves in the rat. This procedure, termed renal-CAP, effectively 
ablates afferent renal nerves, leaving efferent renal nerves intact. This experimental tool 
may be valuable in elucidating the role of afferent renal nerves in animal models of 
hypertension and other cardiovascular diseases and may establish a rationale for 
developing a means for permanent ablation of afferent renal nerves in humans. Moreover, 
the results of our DOCA-salt experiment suggest that afferent renal nerves may be 
involved in some forms of hypertension, making afferent renal nerves both an important 
subject for future basic science research as well as a possible target for human 
hypertension. 
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Figure 1. Representative IHC images stained for CGRP and TH from a SHAM and a 
renal-CAP treated kidney 10 days after treatment. The image on left shows the entire 
slice of the kidney. The boxed in portion of the left image is magnified in the image on 
the right. Brown = CGRP, pink = TH.  
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Figure 2. Tissue content of neurochemical markers 10 days, 4 weeks and 7 weeks 
following SHAM or renal-CAP treatment. A.) IHC labeling of TH. B.) IHC labeling of 
CGRP. C.) NE content of the renal parenchyma by HPLC. D.) CGRP content of the 
pelvic wall by ELISA. ND = not detectable. * = p < 0.05 compared to the 10 day SHAM 
group, † = p < 0.05 compared to the 4 week SHAM group, # = p < 0.05 compared to the 
7 week SHAM group. § = p < 0.05 compared to the 10 day renal-CAP group. 
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Figure 3. Time course of afferent reinnervation following renal-CAP treatment. 
Renal pelvic CGRP content of renal-CAP treated (left) kidneys is expressed as % of 
within animal control (right) kidneys. A linear regression was performed (R2 = 0.65, p < 
0.0001) and group averages ± SE are overlaid. 
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Figure 4. Physiological responses to pharmacological stimulation of afferent renal 
nerves in SHAM and renal-CAP treated rats. Changes in MAP (ΔMAP, top) and HR 
(ΔHR, bottom) following intrarenal (left) and intravenous (right) infusions of bradykinin. 
* = p < 0.05 for SHAM vs. renal-CAP. 
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Figure 5. MAP and HR in SHAM and renal-CAP treated rats subjected to the salt-
sensitivity protocol. * = p < 0.05 for SHAM vs. renal-CAP. 
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Figure 6. Sodium intake, excretion and balance in SHAM and renal-CAP treated rats 
subjected to the salt-sensitivity protocol. There were no significant differences between 
groups. 
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Figure 7. Water intake, urine output and water balance in SHAM and renal-CAP 
treated rats subjected to the salt-sensitivity protocol. * = p < 0.05 for renal-CAP vs. 
SHAM.  
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Table 1. Body weight at the time of treatment (BW at Tx), body weight at sacrifice (Final 
BW) and weight gain from treatment to sacrifice (ΔBW) in SHAM and renal-CAP rats 
that underwent a 10 day, 4 week or 7 week protocol. No significant differences were 
found between SHAM and renal-CAP rats that underwent the same protocol. 
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Figure 8. A.) Average baseline MAP and HR and B.) change in MAP from baseline 
(ΔMAP) and change in HR from baseline (ΔHR) in SHAM, RDNX and renal-CAP 
rats upon DOCA implantation. * = p < 0.05 for RDNX vs. SHAM. # = 0.05 for renal-
CAP vs. SHAM. 
80 
 
 
 
 
 
 
Figure 9. Tissue content of neurochemical markers in the kidneys of rats that 
underwent the DOCA-salt protocol A.) NE content in the renal parenchyma. B.) CGRP 
content in the renal pelvic wall. * = p < 0.05 compared to SHAM. 
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4.1 Summary 
 
Recent clinical data suggest that ablation of renal nerves (renal denervation; RDNX) may 
be a plausible treatment for human hypertension. These studies have also raised the 
question whether the antihypertensive effect of RDNX is due to ablation of afferent or 
efferent renal nerves. Chronic insults to the kidneys have been linked to afferent renal 
nerve-dependent hypertension, and we have previously shown that RDNX lowers arterial 
pressure in hypertensive Dahl salt-sensitive (S) rats, which exhibit renal pathology. Using 
this model, we tested the hypothesis that the antihypertensive effect of RDNX is due to 
ablation of afferent renal nerves by comparing the effect of complete RDNX to selective 
ablation of afferent renal nerves (renal-CAP) during two phases of hypertension in the 
Dahl S rat. In the “early phase” rats underwent treatment after 3 weeks of high NaCl 
feeding when mean arterial pressure (MAP) was ~140 mmHg and kidney disease is 
known to be mild. In the “late phase” rats underwent treatment after 9 weeks of high 
NaCl feeding when MAP was ~170 mmHg and kidney disease is known to be severe. 
RDNX reduced MAP ~10 mmHg compared to SHAM in both the early and late phase. 
Renal-CAP had no antihypertensive effect compared to SHAM. These results suggest 
that, in the Dahl S rat, the antihypertensive effect of RDNX is not dependent on 
pretreatment arterial pressure nor is it due to ablation of afferent renal nerves, even in the 
context of prolonged high NaCl feeding and more severe hypertension and renal 
pathology. 
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4.2 Introduction 
  
Despite the staggering worldwide prevalence of hypertension and its significant 
association with death and disability, little progress has been made in the treatment of this 
disease (108, 131). Recent technological advancements have pointed to catheter based 
ablation of renal nerves (renal denervation; RDNX) as a promising treatment for drug 
resistant hypertension in humans. The efficacy and safety of this device-based approach 
were demonstrated by two small clinical trials, Symplicity HTN-1 and Symplicity HTN-
2. However, a larger sham-controlled trial, Symplicity HTN-3, failed to demonstrate a 
significant therapeutic effect (13).  Although the reason for the failure of Symplicity 
HTN-3 is currently unknown, the results are certainly surprising given the large body of 
earlier clinical and preclinical data demonstrating the efficacy of RDNX in the prevention 
and treatment of hypertension (38, 42, 101). It is clear that further studies designed to 
address the mechanisms underlying the antihypertensive effect of RDNX are needed to 
further refine and optimize this treatment strategy. 
 Since the first clinical studies of RDNX were published, it has been debated 
whether RDNX lowers arterial pressure (AP) secondary to ablation of afferent or efferent 
renal nerves (100). Reductions in efferent renal nerve activity could reduce AP by 
decreasing renin release, tubular sodium reabsorption and/or renal vascular resistance – 
the three primary renal functions influenced by efferent renal nerve activity (38). Indeed 
data from one clinical study suggest that RDNX may reduce renal vascular resistance as 
indicated by a reduction in renal resistive index (112). However, there are no clinical 
studies regarding the effect of RDNX on plasma renin concentrations or sodium balance. 
 Another possibility is that the antihypertensive response to RDNX is due to 
ablation of sympathoexcitatory afferent renal nerves resulting in decreased non-renal 
sympathetic activity. This hypothesis is supported by clinical studies demonstrating 
reductions in muscle sympathetic nerve activity, plasma glucose, cardiac arrhythmias and 
events of sleep apnea following RDNX (67, 149, 171). While these studies have revealed 
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significant physiological consequences of afferent renal nerve ablation, it is still unclear 
whether the antihypertensive effect of RDNX is due to ablation of afferent renal nerves. 
The notion that hypertension can result from elevated afferent renal nerve activity 
is based on a number of studies. First, stimulation of afferent renal nerves has been 
shown to increase AP acutely (135, 150). Second, insults to the kidneys, such as damage 
induced by cortical injection of phenol or chronic ischemia caused by renal artery 
stenosis, have been shown to increase AP chronically in an afferent renal nerve-
dependent manner (22, 167, 173). Lastly, end-stage renal disease patients are known to 
have elevated AP and sympathetic nerve activity both of which are reduced following 
bilateral, but not unilateral renal transplantation, suggesting that signals arising from the 
diseased kidney drive sympathetic outflow and HTN in renal failure patients (63). 
Importantly, patients enrolled in the RDNX trials, on average, had mild kidney disease as 
indicated by reduced glomerular filtration rate (43, 152). Therefore, it is possible that the 
antihypertensive effect of RDNX in people is secondary to a reduction in kidney disease-
induced afferent renal nerve activity.  
We have recently reported that RDNX partially reverses hypertension in the Dahl 
salt-sensitive (Dahl S) rat (48). This genetic model of salt-sensitive hypertension is 
associated with activation of the sympathetic nervous system (138) and marked kidney 
disease that worsens with both age and the progression of hypertension (32). 
Interestingly, the antihypertensive effect of RDNX that we reported is similar to that 
reported following RDNX in patients with ambulatory monitoring of AP (114). However, 
similar to catheter based RDNX in humans, it is unknown whether the antihypertensive 
response to RDNX in Dahl S rats is due to ablation of afferent or efferent renal nerves. 
To investigate the role of afferent renal nerves in hypertension, we recently 
developed and validated a novel method for selective ablation of afferent renal nerves in 
the rat (chapter three). This selective ablation, termed renal-CAP treatment, is achieved 
by periaxonal application of capsaicin, a transient receptor potential vanilloid (TRPV) 1 
receptor agonist, to the renal nerves. Since the majority of afferent fibers in the kidney 
express TRPV1 receptors (166), but efferent renal nerves do not, and because prolonged 
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activation of TRPV1 leads to neurodegeneration (160, 161), renal-CAP causes selective 
degeneration of afferent renal nerves while leaving efferent nerves intact. In this report 
we demonstrated that renal-CAP treatment and RDNX both blunted the development of 
deoxycorticosterone acetate (DOCA)-salt hypertension to a similar extent. This finding 
suggests that the antihypertensive effect of RDNX in the DOCA-salt model is due to 
ablation of afferent renal nerves and provides a “proof of concept” for the utility of this 
novel method to study the role of afferent renal nerves in other preclinical models of 
hypertension. 
In the present study, we used this novel method for selective ablation of afferent 
renal nerves to investigate the mechanisms mediating the antihypertensive effect of 
RDNX in Dahl S rat. We tested the hypothesis that the response to RDNX is due to 
ablation of afferent renal nerves specifically by comparing the antihypertensive effect of 
complete RDNX to that of renal-CAP treatment. Moreover, since kidney disease is a 
possible culprit of afferent renal nerve-dependent hypertension, and Dahl S rats exhibit 
renal pathology that worsens with duration of high NaCl feeding and hypertension, we 
tested this hypothesis in both the early phase (after 3 weeks of high NaCl feeding when 
HTN and renal pathology are mild) and the late phase (after 9 weeks of high NaCl 
feeding when HTN and renal pathology are more severe) of hypertension. 
  
4.3 Methods 
 
Animals and General Procedures 
Male Dahl S rats were purchased from Charles River Laboratories (Wilmington, 
MA) and housed in pairs in a temperature and light controlled room until the beginning 
of the study.  Rats were allowed access to standard rat chow and distilled water ad 
libitum during this pre-experimental period. All procedures were approved by the 
University of Minnesota Animal Care and Use Committee and were conducted in 
accordance with the institutional and National Institutes of Health guidelines. For all 
surgeries, rats were anesthetized with 2.0% isoflurane.  Atropine sulfate (0.4 mg/kg, 
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intraperitoneal) and gentamicin sulfate (10 mg/kg, intramuscular) were administered prior 
to surgery.  For three days following surgery, ketoprofen (2.5 mg/kg, subcutaneous) was 
given once per day and the drinking water was supplemented with amoxicillin (1 mg/ml).   
 
Experimental Protocol 
Rats were subjected to one of the protocols outlined in Figure 1 and described 
below. 
Early phase protocol: 67-74 day old rats were placed on a low salt diet (0.1% 
NaCl; Research Diets, New Brunswick, NJ) and instrumented with radio telemeters 
(model TA11PA-C40, DSI, Intl. St. Paul, MN) for monitoring of mean arterial pressure 
(MAP) and heart rate (HR) as previously described (162). After a 7-day recovery period, 
rats were individually housed in metabolic cages (Techniplast 3701M001, Buguggiate, 
Italy) and allowed to acclimate for four days. Three days of baseline data were then 
collected (see below for details) and rats were placed on a high salt diet (4.0% NaCl; 
Research Diets) for the remainder of the protocol. After 21 days of high salt intake, rats 
were anesthetized with isoflurane and, via a midline approach, subjected to sham 
(SHAM; n = 10), renal denervation (RDNX; n = 10) or selective ablation of afferent renal 
nerves (renal-CAP; n = 10) as previously described (162) (chapter three). Rats were 
returned to their cages and monitored for an additional 4 weeks.  
Late phase protocol: 62-64 day old rats were placed on a high salt diet (4.0% 
NaCl; Research Diets) and, after 49-50 days, were instrumented with radio telemeters 
(DSI, Intl.) for monitoring of MAP and HR. After a 6-7-day recovery period, rats were 
individually housed in metabolic cages (Techniplast) and allowed to acclimate for four 
days. Three days of baseline data were then collected. After 9 weeks total of high salt 
diet, rats were anesthetized with isoflurane and, via a midline approach, subjected to a 
sham (SHAM; n = 8), renal denervation (RDNX; n = 9) or selective ablation of afferent 
renal nerves (renal-CAP; n = 9). Rats were returned to their cages and monitored for an 
additional 2 weeks. 
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 At the end of the study, rats were anesthetized, exsanguinated and kidneys were 
removed immediately after death. The renal artery, renal vein, ureter and capsule were 
removed; and the kidneys were placed in a cold normal saline bath for further dissection. 
Renal parenchymal samples were taken from the poles and lateral portion of the kidney 
and flash frozen in liquid nitrogen. The renal pelvis was then carefully dissected from the 
remaining portion of kidney and flash frozen in liquid nitrogen. All frozen samples were 
stored at -80°C until being assayed. 
 The parenchymal samples were assayed for norepinephrine (NE), a marker of 
efferent renal nerves, using HPLC as previously described (107). The isolated renal 
pelvic samples were assayed for calcitonin gene-related peptide (CGRP), a marker for 
afferent renal nerves, using a commercially available ELISA kit (Cayman Chemicals; 
Ann Arbor, MI; Item Number 589001). Tissues were homogenized in 1M acetic acid and 
CGRP was extracted using C18 Sep-columns (Peninsula Laboratories; San Carlos, CA; 
Item Number Y-1000). To eliminate any interassay variance, all pelvic samples were run 
on single 96 well ELISA plate. 
 
Daily Measurements 
The transmitter signal was monitored by a receiver (Data Sciences, model RPC-1) 
mounted on the side of the metabolic cage and connected to a Data Exchange Matrix 
(Data Sciences, Int). The AP signal was sampled at 500 samples/second for 10 seconds 
every 4 minutes using commercially available software (Data Sciences, Int.). HR was 
determined from the AP profile using the same software. 24-hour (24h) averages of MAP 
and HR were determined and plotted for each day of the study. 
24h food intake, water intake and urine output were measured gravimetrically. 
24h sodium intake was calculated by multiplying food intake (grams) and sodium content 
of the diet (0.1% NaCl = 0.01711 mmol Na
+
/g food; 4.0% NaCl = 0.6844 mmol Na
+
/g 
food). 24h sodium excretion was calculated by multiplying 24h urine output (ml) and 
urinary sodium concentration (mmol Na
+
/ml), which was measured using an ion specific 
electrode (NOVA-5+ electrolyte analyzer, Nova Biomedical, Waltham, MA). 24h sodium 
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and water balances were calculated as 24h intake minus 24h excretion. Cumulative 
sodium and water balance were then calculated by sequential summation of daily 
balances beginning on the day of treatment surgery.  
 
Statistical Analysis 
MAP, HR and cumulative Na
+
/H2O balance data were analyzed by 2-way analysis 
of variance (ANOVA) for repeated measures followed by the Bonferroni method for 
post-hoc comparisons GraphPad Prism v6 (GraphPad Software, San Diego, CA). 
Baseline MAP and HR as well as CGRP and NE data were analyzed by one-way 
ANOVA. A p value less than 0.05 was considered to be statistically significant. 
 
4.4 Results 
 
Early Phase Protocol 
 As shown in Table 1, baseline MAP before treatment (after 3 weeks of high NaCl 
feeding) was similar in all three groups (SHAM = 138.6 ± 3.1 mmHg, RDNX = 139.9 ± 
3.1 mmHg, renal-CAP = 138.1 ± 1.6 mmHg).  MAP dropped transiently in all three 
groups following treatment and then continued to rise throughout the remainder of the 
protocol (Figure 2) and on the final day, MAP was similar in SHAM (161.7 ± 4.5 mmHg) 
and renal-CAP (160.1 ± 4.0 mmHg) rats. However, MAP in RDNX rats was ~10 mmHg 
lower than SHAM and renal-CAP throughout the protocol and MAP on the final day was 
150.5 ± 3.2 mmHg.  
 HR was similar in SHAM (396.4 ± 3.4 BPM), RDNX (401.4 ± 4.2 BPM) and 
renal-CAP (396.0 ± 4.2 BPM) rats on the day before treatment (Table 1). In all three 
groups, HR transiently increased following treatment and then fell slightly below baseline 
(Figure 2). There were no differences in HR between SHAM and renal-CAP rats 
throughout the protocol. Two days after treatment, HR was significantly higher in RDNX 
compared to SHAM and renal-CAP rats. HR was then similar in all groups until about 
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two weeks after treatment when HR in the RDNX group trended lower and was 
statistically significantly lower than SHAM on days 22 and 28.  
 As shown in Figure 2, there were no differences in cumulative sodium or water 
balance between groups at any time following treatment in the early phase protocol. 
 
Late Phase Protocol 
 In rats fed a high NaCl diet for 9 weeks (late phase), pretreatment MAP was 
nearly 30 mmHg higher than rats fed a high NaCl diet for 3 weeks (Table 1). However, 
MAP was similar in all three late phase groups prior to treatment. MAP dropped 
transiently in all three groups after treatment and then continued to rise throughout the 
remainder of the protocol (Figure 3). The initial drop was much greater in the late phase 
protocol than in the early phase protocol; however, MAP was similar in SHAM (178.3 ± 
6.1 mmHg) and renal-CAP (182.0 ± 5.4 mmHg) rats by the end of the protocol. As in the 
early phase protocol, MAP in RDNX rats was ~10 mm Hg lower than SHAM and renal-
CAP rats throughout the late phase protocol and MAP on the final day was 172.7 ± 6.4 
mmHg. 
 As shown in Table 1, the pretreatment HR in the late phase protocol was similar 
between groups and similar to the pretreatment HR in the early phase protocol. On the 
day of treatment HR was significantly higher in renal-CAP rats compared to SHAM and 
significantly higher in RDNX rats compared to both renal-CAP and SHAM. HR was then 
similar between groups throughout the protocol with the exception of day 9 when HR 
was significantly lower in RNDX rats compared to SHAM. 
 As with the early phase protocol, there were no differences in cumulative water 
balance between groups at any time following treatment in the late phase protocol (Figure 
3). However, cumulative sodium balance trended slightly lower in RDNX and renal-CAP 
rats compared to SHAM, but these differences were only significant on the final day of 
the late phase protocol. 
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Renal NE and CGRP content 
 To confirm the denervations, we measured renal tissue content of the afferent 
nerve marker, CGRP and the efferent nerve marker, NE. In both the early and late phase 
protocols, NE and CGRP were significantly reduced in the kidneys of RDNX rats as 
compared to SHAM rats (Figure 4). In both protocols, renal-CAP treatment resulted in a 
reduction in pelvic CGRP content that was even greater than RDNX. Compared to 
SHAM, renal NE content was not reduced in renal-CAP rats in the late phase protocol, 
but was somewhat reduced in renal-CAP rats in the early phase protocol.   
 
4.5 Discussion 
 
Although both preclinical and clinical studies suggest that RDNX has great potential for 
treating drug resistant hypertension, it is unclear whether the antihypertensive effect of 
RDNX is due to ablation of afferent or efferent renal nerves. However, mounting clinical 
evidence suggests that the therapeutic effects of RDNX may indeed be due to ablation of 
afferent renal nerves (67, 149, 171). To address this possibility, we recently developed a 
method to selectively ablate afferent renal nerves and have shown that this method 
attenuates the development of DOCA-salt hypertension to a similar extent as RDNX 
(chapter three). These results suggest that attenuation of DOCA-salt hypertension by 
RDNX is due to ablation of afferent rather than efferent renal nerves. 
We have also previously shown that RDNX partially reverses the early phase of 
Dahl S hypertension (48). In the present study, we investigated whether the 
antihypertensive effect of RDNX in the Dahl S rat is due to ablation of afferent renal 
nerves by comparing the effects of RDNX and renal-CAP treatment.  Moreover, because 
kidney disease has been linked to afferent renal nerve-dependent hypertension (63) and 
because Dahl S rats exhibit progressive renal pathology (32), we tested this hypothesis in 
both the early phase and late phase of Dahl S hypertension.  
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Renal denervation, but not selective ablation of afferent renal nerves, partially 
reverses Dahl S hypertension  
To test whether the antihypertensive effect of RDNX in the Dahl S rat is due to 
ablation of afferent renal nerves, we compared the effect of RDNX and renal-CAP 
treatment on MAP in both the early and phase of Dahl S hypertension. In both protocols, 
RDNX lowered MAP ~10 mmHg compared to SHAM rats. Importantly, selective 
ablation of afferent renal nerves by renal-CAP treatment had no effect on MAP as 
compared to SHAM treatment in either protocol. These data show that, in contrast to our 
hypothesis, and our recent report in the DOCA-salt model, the antihypertensive effect of 
RDNX in the Dahl S rat is not due to ablation of afferent renal nerves. This discrepancy 
is important because it suggests that the mechanisms underlying the antihypertensive 
effect of RDNX vary from model to model and will likely vary from patient to patient.  
It is also interesting to note that, while we have not performed RDNX in Dahl S 
rats prior to high NaCl feeding, we have shown that RDNX lowers MAP ~10 mmHg in 
normotensive Sprague-Dawley rats whereas renal-CAP has no effect on basal MAP (76, 
78). Moreover, RDNX in human subjects has been shown to reduce 24h averaged 
ambulatory MAP ~10 mmHg (114). Taken together, these results suggest that, in the 
absence of stimuli that cause inappropriately high afferent or efferent renal nerve activity, 
basal efferent renal nerve activity may contribute ~10 mmHg to MAP. 
 
The antihypertensive effect of RDNX is similar in both the early and late phase of 
Dahl S hypertension 
 Because kidney disease has been linked to afferent renal nerve-dependent 
hypertension and Dahl S rats exhibit progressive renal pathology (32, 63), we subjected 
Dahl S rats to RDNX  and renal-CAP treatment in both the early phase (after 3 weeks of 
high NaCl feeding), when MAP was ~140 mmHg and renal pathology is known to be 
moderate; and in the late phase (after 9 weeks of high NaCl feeding), when MAP was 
~170 mmHg and renal pathology is known to be more severe (32). Interestingly, the 
antihypertensive effect of RDNX was nearly identical in both the early and late phase of 
92 
 
Dahl S hypertension, and renal-CAP had no effect in either phase. These results have two 
important implications. First, the degree to which RDNX reverses HTN in the Dahl S rat 
appears not to be dependent on the duration of high salt feeding or pretreatment AP. This 
suggests that, in contrast to previous reports, baseline AP may be a poor predictor of the 
antihypertensive effect of RDNX (152). Second, these data suggest that, even in the 
presence of renal pathology, afferent renal nerves may not drive hypertension. 
 This study suggests that kidney disease is not necessarily associated with afferent 
renal nerve-dependent hypertension. However, we cannot exclude the possibility that 
kidney disease may drive hypertension via afferent renal nerves in other models. We have 
recently shown that renal-CAP treatment is effective in attenuating the development of 
DOCA-salt hypertension, a model in which rats are uninephrectomized and severe renal 
pathology results in the remaining kidney (119). Therefore, while renal pathology did not 
lead to afferent renal nerve-dependent hypertension in either phase of Dahl S 
hypertension, it may play a role in the DOCA-salt model. Further studies will be needed 
to determine the precise circumstances in which kidney disease can causes elevations in 
afferent renal nerve activity and AP. 
 
The antihypertensive effect of RDNX is not due to sodium and water unloading 
 While total assessment of the efferent renal nerve specific responses to RDNX 
(i.e. plasma renin concentration and renal vascular resistance) was outside of the scope of 
this study, we did measure whole body cumulative sodium and water balance. These 
measurements revealed that the antihypertensive effect of RDNX did not correspond with 
a reduction in sodium or water balance. These results demonstrate that a reduction in AP 
can occur in the absence of enhanced natriuresis and diuresis. This finding is consistent 
with our earlier report on the effect of RDNX in Dahl S rats (48). These data, combined 
with our findings that afferent renal nerves do not play role in this model, suggest that the 
antihypertensive effect of RDNX in the Dahl S rat is likely due to either reduced activity 
of the renin angiotensin system or a reduction in renal vascular resistance. Further 
investigation will be needed to test these possibilities. 
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HR is largely unaffected by RDNX and renal-CAP 
 Our previous work has suggested that renal nerves may play a minor role in the 
long-term regulation of heart rate. Specifically, renal-CAP treatment resulted in a 
blunting of the bradycardic response to dietary sodium loading in normotensive Sprague-
Dawley rats. Alternatively, the bradycardic response to DOCA-salt hypertension was 
actually enhanced in RDNX rats compared to SHAM rats despite the antihypertensive 
effect of RDNX (77). Interestingly, there was a slightly enhanced bradycardia in the early 
phase of Dahl S hypertension in this study. While the effect was minor and only 
significant on a few days, these results are consistent with some minor role of the renal 
nerves in heart rate regulation. This recurring phenomenon merits further investigation in 
order to uncover the mechanisms involved.  
 
4.6 Perspectives 
 
While RDNX appears to be a promising treatment option for drug resistant hypertension, 
the mechanisms underlying this therapeutic effect remain unclear. In order to further 
optimize this treatment, it is important to determine whether the antihypertensive effect is 
due to ablation of afferent or efferent renal nerves. To this end, we have shown that the 
antihypertensive effect of RDNX in the Dahl S rat is not due to ablation of afferent renal 
nerves. This is in contrast to our previous study in the DOCA-salt model in which renal-
CAP treatment blunted the development of hypertension (chapter three). These results are 
critically important because they suggest that the mechanisms underlying the 
antihypertensive effect of RDNX will likely vary from patient to patient. Therefore, it 
may be optimal to develop selective ablation techniques, which could be used to target 
either subset of renal nerves in order to optimize efficacy and minimize side effects. 
Furthermore, it may be possible to develop clinical tests to identify patients that would 
benefit from such selective ablations. Further animal studies will be critical in developing 
such tests. 
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Novelty and significance 
What Is New? 
 The antihypertensive effect of RDNX in the Dahl S rat is unrelated to the duration 
of high NaCl feeding, pretreatment AP or degree of kidney disease 
 The antihypertensive effect of RDNX in the Dahl S rat appears not to be due to 
ablation of afferent renal nerves. 
What Is Relevant? 
 The recent failure of one clinical trial has highlighted the importance of 
understanding how RDNX lowers arterial pressure when it does. 
 The degree to which RDNX lowers MAP in the Dahl S rat is similar to what has 
been reported in human patients  
 The mechanisms underlying the antihypertensive effect of RDNX appear to vary 
from model to model and will likely vary from patient to patient 
Summary 
 The results of this study suggest that the antihypertensive effect of RDNX in the 
Dahl S rat is not dependent on pretreatment AP or degree of kidney disease nor is it due 
to ablation of afferent renal nerve. If the same is true in some people, selective ablation of 
efferent renal nerves may be preferred. 
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Table 1. Average mean arterial pressure (MAP) and heart rate (HR) on the day before 
treatment surgery in SHAM, RDNX and renal-CAP rats in the early phase (top) and late 
phase (bottom) protocols. There were no statistical differences in MAP or HR between 
groups in either protocol. 
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Figure1. Detailed description of the early phase and late phase protocols.  
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Figure 2. Change in mean arterial pressure (ΔMAP), change in heart rate (ΔHR), 
cumulative sodium (Na+) balance, and cumulative water (H2O) balance following 
SHAM, RDNX or renal-CAP treatment in the early phase protocol. * = p <0.05 for 
RDNX vs. SHAM. † = = p <0.05 for RDNX vs. renal-CAP. 
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Figure 3. Change in mean arterial pressure (ΔMAP), change in heart rate (ΔHR), 
cumulative sodium (Na+) balance, and cumulative water (H2O) balance following 
SHAM, RDNX or renal-CAP treatment in the late phase protocol. * = p <0.05 for 
RDNX vs. SHAM. † = = p <0.05 for RDNX vs. renal-CAP, ‡ = p <0.05 for renal-CAP 
vs. SHAM. 
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Figure 4. Content of the afferent nerve marker calcitonin gene-related peptide 
(CGRP; top) and the efferent nerve marker norepinephrine (NE; bottom) in the 
kidneys of SHAM, RDNX and renal-CAP rats at the end of the early phase (left) and 
late phase (right) protocols. * = p <0.05 for RDNX vs. SHAM. † = = p <0.05 for RDNX 
vs. renal-CAP. 
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Chapter Five 
 
Conclusions 
  
 
 
 
 
 
 
 
Clinical data suggest that RDNX may be an effective antihypertensive treatment in drug 
resistant human patients, but the mechanisms underlying this therapeutic effect remain 
unclear. Because RDNX works by destroying all types of nerves in the kidney, it is of 
great interest whether the decrease AP seen with this treatment is secondary to ablation of 
afferent or efferent renal nerves. The focus of my work has been centered on the 
hypothesis that the antihypertensive effect of RDNX is due to ablation of afferent rather 
than efferent renal nerves. In order to test this hypothesis, I first identified an animal 
model of HTN in which RDNX lowers AP. We found that RDNX had a significant 
antihypertensive effect in a commonly used genetic model of salt-sensitive HTN, the 
Dahl S rat. In this model, RDNX lowered MAP ~10-15 mmHg, a similar 
antihypertensive effect to the one observed in 24 hr. averaged ambulatory measurements 
in people. I then developed and validated a novel method for selective ablation of afferent 
renal nerves. We showed that 15 minute exposure of the renal nerves to capsaicin (renal-
CAP treatment) causes both anatomical and functional ablation of afferent, but not 
efferent renal nerves. Using this technique, I then tested whether the antihypertensive 
effect of RDNX is due to ablation of afferent renal nerves in mildly hypertensive Dahl S 
rats fed a high salt diet for three weeks (early phase) and in severely hypertensive Dahl S 
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rats fed a high salt diet for nine weeks (late phase). The results of this final experiment 
suggested that the antihypertensive effect of RDNX in Dahl S is not due to ablation of 
afferent renal nerves. Moreover, the therapeutic effect of RDNX was equal in both phases 
of Dahl S HTN, suggesting that the antihypertensive effect of RDNX is not dependent on 
the duration of high salt feeding or pretreatment MAP. In this final chapter I will discuss 
the significance of these finding as well the importance of some of the ancillary findings 
of these experiments. 
 
Renal-CAP treatment: a novel method for selective ablation of afferent renal nerves 
Perhaps the most significant contribution of my work to the field of HTN research 
is the development and validation of a novel method for selective ablation of afferent 
renal nerves. While other methods have been used to indirectly investigate the 
physiological roles of afferent renal nerves, our renal-CAP method is the first technique 
developed to selectively and specifically ablate afferent renal nerves. That is, it causes 
ablation of afferent renal nerves without affecting efferent renal nerves or any non-renal 
nerves. Because this technique allows for specific investigation into the role of afferent 
renal nerves, and because the debate over the role of afferent vs efferent renal nerves in 
HTN is a hot one, this technique has great potential to influence future basic science 
research, which may in turn inform future clinical research.  
 
Additive effect of multiple targeted sympathetic denervations 
Another important finding was that independent denervations have the potential to 
have an additive antihypertensive effect. The observation that, in the Dahl S rat, RDNX 
and CGX each have an antihypertensive effect was interesting, but even more interesting 
was that these two procedures had an additive effect when done in conjunction. This 
important result suggests that human hypertensives may benefit from a multipronged 
approach. That is, certain patients who undergo an ablation of one sympathetic target 
may benefit from an additional ablation procedure. While current technology does not 
allow for any simple means of denervating non-renal targets, future technological 
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advances may make it feasible to target multiple sympathetic pathways with added 
benefit.  
 
RDNX reduces AP in the absence of unloading of sodium and water 
One prominent hypothesis regarding the mechanisms underlying the 
antihypertensive effect of RDNX is centered on the idea that removal of efferent renal 
nerves causes natriuresis and diuresis and thereby decreases AP. While this hypothetical 
model seems feasible, my data directly challenge this idea. Multiple experiments done in 
the Dahl S rat showed significant reductions in AP with RDNX independent of changes 
in sodium and water balance compared to sham operated controls. These data add to the 
growing body of evidence suggesting that chronic reductions in AP can occur in lieu of 
changes in renal excretory function. 
   
Challenging previous studies: ablation of afferent renal nerves does not result in 
salt-sensitive HTN 
Also important was the observation that afferent renal nerves are not required to 
maintain cardiovascular or salt and water homeostasis in the rat. Our data showing that 
rats are able to regulate sodium/water balance as well as AP and, to a large extent, HR 
challenge the hypothesis that afferent renal nerves are crucial in maintaining 
cardiovascular and salt/water homeostasis in the context of high dietary sodium intake. 
While further studies are needed to explain why afferent denervation that is not specific 
to the kidney (i.e. dorsal rhizotomy or systemic capsaicin) results in salt-sensitive HTN, it 
is clear from my data that selective ablation of afferent renal nerves does not lead to salt-
sensitive HTN. This point becomes increasingly important when we begin to consider 
selective ablation procedures. Specifically, it may be preferable to perform selective 
ablation of afferent renal nerves in some patients. It is therefore important to know that 
this type of selective ablation would not result in salt-sensitivity, which would be a major 
side effect.  
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How this work informs the future of clinical HTN treatment 
When data from the initial human RDNX trials were published, it appeared as 
though RDNX may be a universally effective treatment for drug resistant HTN. However, 
at least two recent trials have failed to show a significant antihypertensive effect of 
RDNX (13, 18). The reason for the discrepancy in these results remains unclear at present 
time, but there are a number of hypotheses ranging from different device design to user 
error on the interventionalists’ part. While we may never know the exact cause for the 
failure of these trials, our animal studies shed some light on this controversy. 
 In the course of my studies, I have performed RDNX in various animal models of 
HTN. Moreover, RDNX has been used in an attempt to either prevent or reverse nearly 
every animal model of HTN in the past (38). In this thesis I have described the effect of 
RDNX on the reversal of Dahl S HTN and the prevention of DOCA-salt HTN. While 
RDNX did have an antihypertensive effect in both of these models, our lab has 
previously shown that RDNX has no effect on the development of a commonly used 
model of HTN, the AngII-salt model in which AngII is given subcutaneously and the rats 
are fed a high sodium diet (91). In addition, I performed a study (not included in this 
thesis) showing that RDNX does not prevent the development of the i.v. AngII-salt 
model in which AngII is given intravenously and rats are fed a high sodium diet.  
The question then arises, which model is the right model for human HTN? The 
answer to this question is rather unsatisfying – we don’t know. The reason that we cannot 
know for certain which model of HTN mimics human HTN best is that, just as all models 
of HTN are different, not all human hypertensives are the same. Therefore, the cautionary 
lesson to be learned from all of this is that RDNX likely will not be an effective 
antihypertensive treatment for all patients. The plethora of animal data and the growing 
body of clinical data supporting this assertion suggest that it would be logical for the 
device industry to take a step back and focus on a couple of key points. First, as RDNX 
likely will not work for all hypertensive patients, there is a great need to develop a 
reliable means to determine which patients will benefit from RDNX. Second, the 
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mechanisms underlying the antihypertensive effect of RDNX need to be identified in 
order to optimize the treatment.  
Within the field, there has been a great deal of debate over whether RDNX lowers 
AP, when it does, by removing sympathetic control of the kidneys, or by removing 
sympathoexcitatory input from afferent renal nerves. While it has been impossible to 
answer this question in human patients, there is some clinical data supporting both 
hypotheses. Specifically, RDNX has been shown to reduce renal resistive index 
(presumably due to ablation of efferent renal nerves) as well as non-renal SNA, plasma 
glucose, incidence of sleep apnic events and severity of cardiac arrhythmias (all 
presumably due to ablation of afferent renal nerves) (67, 112, 149, 171).  
While clinicians have not been able to resolve this debate in people, the animal 
studies described in this thesis shed some light on a possible answer. Using two different 
animal models of HTN, I have shown that the antihypertensive effect of RDNX can be 
due to ablation of either afferent or efferent renal nerves. Specifically, while RDNX 
attenuated HTN both in the Dahl S rat and the DOCA-salt model, selective ablation of 
afferent renal nerves with renal-CAP treatment attenuated only DOCA-salt HTN. As 
stated earlier, we do not know which model better represents human HTN since there are 
many forms of human HTN. Therefore, these results suggest that when RDNX lowers AP 
in people, it may be due to ablation of afferent or efferent renal nerves depending on the 
type of HTN the patient has. This is an important point because we may be able to 
develop selective ablation techniques to target either afferent or efferent renal nerves, 
specifically. 
If it is indeed true that there are patients who could benefit from selective ablation 
of either afferent or efferent renal nerves, there may be a number of benefits to 
developing selective ablation techniques. First, because there is an issue achieving 
complete denervation with current technology (41), selective ablation techniques may 
result in more complete ablation of either afferent or efferent renal nerves. Indeed, my 
data showed consistently that renal-CAP treatment reduces pelvic CGRP content to 
greater extent than complete RDNX. Furthermore, since nearly all afferent renal nerves 
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are thought to innervate the pelvic wall, intrapelvic administration of a selective 
neurotoxin may result in a more complete ablation of afferent renal nerves, although this 
anatomical advantage does not exist for selective ablation of efferent renal nerves. 
The second possible benefit of selective ablation is a minimization of side effects. 
It should be noted that there have been very few side effects reported following RDNX. 
However, there is a concern that if a renal denervated patient is in an extreme situation 
such as hemorrhage or extreme water deprivation, the absence of sympathetic control of 
the kidney would be detrimental. Therefore, if a patient’s HTN is driven by ARNA, 
selective ablation of afferent renal nerves would be preferred as it would preserve the 
efferent renal nerves for these types of extreme circumstances. Likewise, preservation of 
the sensory fibers of the kidneys may be preferred if they are not contributing to HTN. 
For example, if a patient has a kidney stone, we know that the kidney sends important 
pain signals to the brain. In the absence of afferent renal nerves, kidney stones would 
likely go undetected and untreated causing greater damage. In this situation, it would be 
preferable to selectively ablate efferent renal nerves. Of course, the key to this treatment 
strategy would be to identify patients who would benefit from selective ablation of either 
afferent or efferent renal nerves.  
In order to better identify those patients who would benefit from RDNX or 
selective ablation, there is a need to develop clinical tests that would help determine 
patient eligibility. To date, the only factors that have been identified as a predictors of the 
efficacy of RDNX to low AP are pretreatment MAP and use of sympatholytic drugs 
(152). That is, RDNX has been shown to be a more effective antihypertensive treatment 
in patients who are more hypertensive and those who respond well to sympatholytic 
drugs. While this may be of some help, identification of biomarkers that could help 
predict the efficacy of RDNX to lower AP would be preferred. Moreover, biomarkers 
may be able to help doctors identify those patients who would benefit from selective 
ablation of afferent or efferent renal nerves.  
While little effort has been made to identify such predictive biomarkers, it is not 
inconceivable. For example, patients with elevated afferent renal nerve activity will likely 
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have elevated levels of afferent neurotransmitters in their urine since these fibers reside 
predominantly in the renal pelvis which is the final collection point for urine in the 
kidney. An index of ERSNA may be more difficult to identify as urinary NE and 
dopamine content have been shown to be poor indicators of ERNSA (95). While difficult, 
the development of such clinical indicators of ARNA and ERSNA merits further 
research. 
 
Unanswered questions 
If RDNX lowers AP in the Dahl S rat secondary to ablation of efferent renal 
nerves, what specific efferent renal nerve function is responsible for the antihypertensive 
effect? While, we do not have a definitive answer to this question, we can eliminate the 
possibility that the drop in AP is secondary to increased natriuresis and diuresis as RDNX 
does not alter sodium or water balance in the Dahl S rat. The other two primary 
candidates then are changes in plasma renin concentration or renal vascular resistance.  
Renin, the rate limiting enzyme in the renin-angiotensin system, is well known to 
play a role in some forms of HTN and therefore a reduction in circulating renin levels 
following RDNX could explain the antihypertensive effect of the treatment. However, 
this is unlikely to explain the therapeutic effect of RDNX in the Dahl S rat since this 
model has been shown to be a low renin model (138). That is, because hypertensive Dahl 
S rats have very low levels of plasma renin, RDNX likely does not effectively lower 
renin levels further. While it is unlikely that RDNX lowers renin levels in Dahl S rats, 
this still merits investigation to explicitly exclude the possibility. 
A much more likely explanation is that RDNX lowers AP in the Dahl S rat 
secondary to reductions in renal vascular resistance. Because the kidneys receive roughly 
one fifth of the total cardiac output (140), and because efferent renal nerve activity has 
been shown to exhibit powerful control over renal blood flow (179), it is logical to posit 
that RDNX causes a reduction in renal vascular resistance and thereby total peripheral 
resistance and systemic AP. This hypothesis is strengthened by the clinical observation in 
one study that the decrease in AP following catheter based RDNX is associated with a 
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reduction in renal resistive index (112). Again, this possible explanation remains to be 
tested. 
 Why is it that the antihypertensive effect of RDNX is due to ablation of afferent 
renal nerves in the DOCA-salt model, but due to ablation of efferent renal nerves in the 
Dahl S rat? While it is important and interesting that the antihypertensive effect of 
RDNX appears to be due to ablation of afferent renal nerves in the DOCA-salt model, but 
due to ablation of efferent renal nerves in the Dahl S rat, this discrepancy raises the 
question of why.  Rather, what is it that causes afferent renal nerves to drive HTN in one 
model and what causes the efferent renal nerves to drive HTN in another. The reason this 
question is so important is that, as discussed earlier, there are likely some patients who 
could benefit from selective ablation of either afferent or efferent renal nerves and 
therefore identifying factors that drive each subset of nerves will be crucial in 
determining which treatment would benefit which patients.  
One possibility is that kidney disease can drive HTN via activation of afferent 
renal nerves. The results shown in chapter four demonstrate that, in the Dahl S rat, which 
is known to exhibit marked kidney disease, the antihypertensive effect of RDNX in not 
due to ablation of afferent renal nerves. However, this does not exclude the possibility 
that renal damage can lead to afferent renal nerve-dependent HTN. This may in fact be 
the case in the DOCA-salt model. It is important to remember that in this model, one 
kidney is removed and, after significant compensatory renal hypertrophy occurs, a salt 
retaining hormone is supplemented and rats are given saline rather than water to drink. In 
other words, renal excretory capacity is impaired and rats take in excessive amounts of 
salt. It is perhaps not surprising that the remaining kidney incurs significant damage as a 
result. It is therefore possible that the afferent renal nerve-dependent HTN observed in 
the DOCA-salt model is a result of excessive renal inflammation that occurs as a result of 
such severe renal damage.  
Moreover, while kidney disease clearly does not cause afferent renal nerve-
dependent HTN in the Dahl S rat, it is possible that if the kidneys incurred greater 
damage, that the afferent renal nerves would become overactive, further driving HTN in 
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this model. Although the results of the Dahl S studies suggest that kidney disease does 
not necessarily drive afferent renal nerves and HTN, the results of the DOCA-salt study 
along with a small body of clinical data warrant further research into the possible link 
between kidney disease and afferent renal nerve-dependent HTN. 
Are there afferent renal nerve fibers that are unaffected by renal-CAP treatment? 
The likely answer to this question is yes. Because the vast majority of afferent fibers in 
the kidney have been shown to be CGRP+, unmyelinated or thinly myelinated, and 
capsaicin sensitive; we have assumed that renal-CAP treatment affects nearly all of the 
afferent renal nerves (39, 92, 128, 166). However, it is likely that some afferent renal 
nerves are TRPV1- and therefore unaffected by capsaicin treatment. Because we used 
CGRP as our marker for afferent renal nerves, we are unable to assess the presence of 
CGRP- fibers in the kidneys. While we were unable to devise a method to quantify the 
entire afferent renal nerve population, it may be possible. Use of a pan-neuronal marker 
may be useful in this regard. It may be possible, using IHC, to label all neurons in the 
kidney and double label for TH in order to exclude efferent fibers. The remaining fibers 
that are positive only for the pan-neuronal marker would be assumed to be the entire 
population of afferent renal nerves. This type of experiment merits further consideration. 
 
Final Thoughts 
The original goal of my work was to determine the differential role of afferent and 
efferent renal nerves in HTN. In order to achieve this goal, I conducted numerous 
experiments, the results of which have a number of important implications. First, my 
work has supplied the field with a new method that will be helpful in answering 
important questions regarding the physiology of afferent renal nerves. Second, my work 
informs the clinical treatment of HTN in that it suggests that 1) it is likely that not every 
patient will benefit from RDNX, 2) selective ablation procedures may be both feasible 
and preferred to complete RDNX and 3) additional ablation procedures performed either 
alone or in conjunction with RDNX should be pursued as possible treatment modalities 
for clinical HTN. 
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